1
|
Gagneux-Brunon A, Dauby N, Launay O, Botelho-Nevers E. Attitudes towards monkeypox vaccination among healthcare workers in France and Belgium: an element of complacency? J Hosp Infect 2022; 130:144-145. [PMID: 36174773 PMCID: PMC9534062 DOI: 10.1016/j.jhin.2022.09.010] [Citation(s) in RCA: 10] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/01/2022] [Revised: 09/15/2022] [Accepted: 09/19/2022] [Indexed: 12/04/2022]
Affiliation(s)
- A Gagneux-Brunon
- Centre International de Recherche en Infectiologie, Team GIMAP, Univ Lyon, Université Jean Monnet, Université Claude Bernard Lyon 1, Inserm, U1111, CNRS, UMR530, France; CIC INSERM 1408 Vaccinologie, CHU de Saint-Etienne, France; Chaire PREVACCI, Université Jean Monnet, Saint-Etienne, France.
| | - N Dauby
- Department of Infectious Diseases, CHU Saint-Pierre - Université Libre de Bruxelles, Brussels, Belgium; School of Public Health, Université Libre de Bruxelles, Brussels, Belgium
| | - O Launay
- Université Paris Cité, Inserm CIC 1417, F-CRIN I-REIVAC, Assistance Publique - Hôpitaux de Paris, Hôpital Cochin, Paris, France
| | - E Botelho-Nevers
- Centre International de Recherche en Infectiologie, Team GIMAP, Univ Lyon, Université Jean Monnet, Université Claude Bernard Lyon 1, Inserm, U1111, CNRS, UMR530, France; CIC INSERM 1408 Vaccinologie, CHU de Saint-Etienne, France; Chaire PREVACCI, Université Jean Monnet, Saint-Etienne, France
| |
Collapse
|
2
|
Gagneux-Brunon A, Bonneton M, Sambourg J, Emran O, Faure-Borkey S, Luong L, Botelho-Nevers E, Launay O. Un volontaire aux essais vaccinaux COVID-19 serait-il prêt à participer à un essai clinique vaccinal non COVID-19 ? MÉDECINE ET MALADIES INFECTIEUSES FORMATION 2022. [PMCID: PMC9152481 DOI: 10.1016/j.mmifmc.2022.03.273] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Download PDF] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
Abstract
Introduction Matériels et méthodes Résultats Conclusion
Collapse
|
3
|
Labetoulle R, Rigaill J, Lleres-Vadeboin M, Grattard F, Pozzetto B, Cazorla C, Botelho-Nevers E, Boyer B, Dupieux-Chabert C, Laurent F, Verhoeven PO, Carricajo A. Evaluation of the MRSA/SA ELITe MGB Assay for the Detection of Staphylococcus aureus in Bone and Joint Infections. J Clin Microbiol 2022; 60:e0083521. [PMID: 34788112 PMCID: PMC8769721 DOI: 10.1128/jcm.00835-21] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/08/2021] [Accepted: 11/15/2021] [Indexed: 11/20/2022] Open
Abstract
Bone and joint infections represent a potentially devastating complication of prosthetic orthopedic joint replacement, thus requiring both rapid and appropriate antibiotic treatment. Staphylococcus aureus is one of the most common pathogens involved in this pathology. Being able to assert its presence is the first step of efficient patient management. This monocenter study evaluated the MRSA/SA ELITe MGB assay for the molecular detection of S. aureus and methicillin-resistant S. aureus (MRSA) in bone and joint biopsy specimens and synovial fluids. This test, together with conventional techniques, including standard cultures and the 16S rRNA amplification assay, was performed on 208 successive perioperative samples collected prospectively for 1 year obtained from 129 patients. Using conventional techniques, we detected a microbial pathogen in 76 samples from 58 patients, 40 of which were identified as S. aureus. The limit of detection (LOD) of the MRSA/SA ELITe MGB assay was experimentally determined for bone and joint biopsy specimens and synovial fluids using negative samples spiked with S. aureus ATCC 43300. The sensitivities of S. aureus detection with the MRSA/SA ELITe MGB assay were 82.5% (33/40 samples) and 97.5% (39/40 samples) using the manufacturer's LOD and an experimentally determined LOD, respectively. Interestingly, using the osteoarticular specific LOD, 15 additional samples were determined to be positive for S. aureus DNA with the MRSA/SA ELITe MGB assay; in all cases, these samples were obtained from patients considered to be infected with S. aureus according to their clinical and microbiological records. The results were available within 24 h, which could help to expedite therapeutic decisions.
Collapse
Affiliation(s)
- R. Labetoulle
- Laboratory of Infectious Agents and Hygiene, University Hospital of St-Etienne, St-Etienne, France
| | - J. Rigaill
- Laboratory of Infectious Agents and Hygiene, University Hospital of St-Etienne, St-Etienne, France
- CIRI, Centre International de Recherche en Infectiologie, GIMAP team, University of Lyon, University of St-Etienne, INSERM, U1111, CNRS UMR5308, ENS de Lyon, UCBL, St-Etienne, France
| | - M. Lleres-Vadeboin
- Laboratory of Infectious Agents and Hygiene, University Hospital of St-Etienne, St-Etienne, France
- Interregional Reference Centre for Complex Bone and Joint Infection (CRIOAc Lyon, Associated Center), University Hospital of St-Etienne, St-Etienne, France
| | - F. Grattard
- Laboratory of Infectious Agents and Hygiene, University Hospital of St-Etienne, St-Etienne, France
- CIRI, Centre International de Recherche en Infectiologie, GIMAP team, University of Lyon, University of St-Etienne, INSERM, U1111, CNRS UMR5308, ENS de Lyon, UCBL, St-Etienne, France
| | - B. Pozzetto
- Laboratory of Infectious Agents and Hygiene, University Hospital of St-Etienne, St-Etienne, France
- CIRI, Centre International de Recherche en Infectiologie, GIMAP team, University of Lyon, University of St-Etienne, INSERM, U1111, CNRS UMR5308, ENS de Lyon, UCBL, St-Etienne, France
| | - C. Cazorla
- Interregional Reference Centre for Complex Bone and Joint Infection (CRIOAc Lyon, Associated Center), University Hospital of St-Etienne, St-Etienne, France
- Department of Infectious Diseases, University Hospital of St-Etienne, St-Etienne, France
| | - E. Botelho-Nevers
- CIRI, Centre International de Recherche en Infectiologie, GIMAP team, University of Lyon, University of St-Etienne, INSERM, U1111, CNRS UMR5308, ENS de Lyon, UCBL, St-Etienne, France
- Department of Infectious Diseases, University Hospital of St-Etienne, St-Etienne, France
| | - B. Boyer
- Interregional Reference Centre for Complex Bone and Joint Infection (CRIOAc Lyon, Associated Center), University Hospital of St-Etienne, St-Etienne, France
- Department of Orthopaedic Surgery, University Hospital of St-Etienne, St-Etienne, France
| | - C. Dupieux-Chabert
- CIRI, Centre International de Recherche en Infectiologie, Staphylococcal Pathogenesis Team, University of Lyon, INSERM U1111, CNRS UMR5308, ENS de Lyon, UCBL, Lyon, France
- Department of Bacteriology, Institute for Infectious Agents, Hôpital de la Croix-Rousse, Hospices Civils de Lyon, Lyon, France
- French National Reference Center for Staphylococci, Lyon, France
- Interregional Reference Centre for Complex Bone and Joint Infection (CRIOAc Lyon), Hospices Civils de Lyon, Lyon, France
| | - F. Laurent
- CIRI, Centre International de Recherche en Infectiologie, Staphylococcal Pathogenesis Team, University of Lyon, INSERM U1111, CNRS UMR5308, ENS de Lyon, UCBL, Lyon, France
- Department of Bacteriology, Institute for Infectious Agents, Hôpital de la Croix-Rousse, Hospices Civils de Lyon, Lyon, France
- French National Reference Center for Staphylococci, Lyon, France
- Interregional Reference Centre for Complex Bone and Joint Infection (CRIOAc Lyon), Hospices Civils de Lyon, Lyon, France
| | - P. O. Verhoeven
- Laboratory of Infectious Agents and Hygiene, University Hospital of St-Etienne, St-Etienne, France
- CIRI, Centre International de Recherche en Infectiologie, GIMAP team, University of Lyon, University of St-Etienne, INSERM, U1111, CNRS UMR5308, ENS de Lyon, UCBL, St-Etienne, France
- Interregional Reference Centre for Complex Bone and Joint Infection (CRIOAc Lyon, Associated Center), University Hospital of St-Etienne, St-Etienne, France
| | - A. Carricajo
- Laboratory of Infectious Agents and Hygiene, University Hospital of St-Etienne, St-Etienne, France
- CIRI, Centre International de Recherche en Infectiologie, GIMAP team, University of Lyon, University of St-Etienne, INSERM, U1111, CNRS UMR5308, ENS de Lyon, UCBL, St-Etienne, France
- Interregional Reference Centre for Complex Bone and Joint Infection (CRIOAc Lyon, Associated Center), University Hospital of St-Etienne, St-Etienne, France
| |
Collapse
|
4
|
Lefebvre M, Vignier N, Pitard B, Botelho-Nevers E, Wyplosz B, Cohen R, Epaulard O. COVID-19 vaccines: Frequently asked questions and updated answers. Infect Dis Now 2021; 51:319-333. [PMID: 33681861 PMCID: PMC7910656 DOI: 10.1016/j.idnow.2021.02.007] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/14/2021] [Accepted: 02/23/2021] [Indexed: 12/29/2022]
Abstract
At the end of December 2019, China notified the World Health Organization about a viral pneumonia epidemic soon to be named COVID-19, of which the infectious agent, SARS-CoV-2, was rapidly identified. Less than one year later, published phase 3 clinical trials underlined the effectiveness of vaccines utilizing hitherto unusual technology consisting in injection of the messenger RNA (m-RNA) of a viral protein. In the meantime, numerous clinical trials had failed to identify a maximally effective antiviral treatment, and mass vaccination came to be considered as the strategy most likely to put an end to the pandemic. The objective of this text is to address and hopefully answer the questions being put forward by healthcare professionals on the different anti-SARS-CoV-2 vaccines as regards their development, their modes of action, their effectiveness, their limits, and their utilization in different situations; we are proposing a report on both today's state of knowledge, and the 14 February 2021 recommendations of the French health authorities.
Collapse
Affiliation(s)
- M Lefebvre
- Service des maladies infectieuses et tropicales, centre de prévention des maladies infectieuses et transmissibles, centre hospitalo-universitaire Hôtel-Dieu, Inserm CIC1413, 1, place Alexis-Ricordeau, 44000 Nantes, France.
| | - N Vignier
- Centre d'investigation clinique Antilles Guyane, CIC Inserm 1424, DRISP, centre hospitalier Andrée-Rosemon, Cayenne, French Guyana; Inserm, Sorbonne université, institut Pierre-Louis d'épidémiologie et de santé publique, IPLESP, 75012 Paris, France; Department of infectious disease, Groupe hospitalier Sud Ile-de-France, 77000 Melun, France
| | - B Pitard
- Université de Nantes, CNRS ERL6001, Inserm 1232, CRCINA, Nantes, France
| | - E Botelho-Nevers
- Service d'infectiologie, centre hospitalo-universitaire de Saint-Étienne, CIC 1408 Inserm, 42055 Saint-Étienne, France; Centre international de recherche en infectiologie (CIRI), Team GIMAP, université Lyon, université Jean-Monnet, université Claude-Bernard Lyon 1, Inserm, U1111, CNRS, UMR530, 42023 Saint-Étienne, France
| | - B Wyplosz
- Service des maladies infectieuses et tropicales, Assistance publique-hôpitaux de Paris, Centre hospitalier universitaire Bicêtre, Paris, France
| | - R Cohen
- InfoVac, centre hospitalier intercommunal de Créteil, service de pédiatrie, 40, avenue de Verdun, 94000 Créteil, France
| | - O Epaulard
- Service des maladies infectieuses, centre hospitalo-universitaire Grenoble Alpes, Grenoble, France, CIC 1406 Inserm, Grenoble, France
| |
Collapse
|
5
|
Cotte L, Hocqueloux L, Lefebvre M, Pradat P, Bani-Sadr F, Huleux T, Poizot-Martin I, Pugliese P, Rey D, Cabié A, Chirouze C, Drobacheff-Thiébaut C, Foltzer A, Bouiller K, Hustache-Mathieu L, Lepiller Q, Bozon F, Babre O, Brunel AS, Muret P, Chevalier E, Jacomet C, Laurichesse H, Lesens O, Vidal M, Mrozek N, Aumeran C, Baud O, Corbin V, Goncalvez E, Mirand A, brebion A, Henquell C, Lamaury I, Fabre I, Curlier E, Ouissa R, Herrmann-Storck C, Tressieres B, Receveur MC, Boulard F, Daniel C, Clavel C, Roger PM, Markowicz S, Chellum Rungen N, Merrien D, Perré P, Guimard T, Bollangier O, Leautez S, Morrier M, Laine L, Boucher D, Point P, Cotte L, Ader F, Becker A, Boibieux A, Brochier C, Brunel-Dalmas F, Cannesson O, Chiarello P, Chidiac C, Degroodt S, Ferry T, Godinot M, Livrozet JM, Makhloufi D, Miailhes P, Perpoint T, Perry M, Pouderoux C, Roux S, Triffault-Fillit C, Valour F, Charre C, Icard V, Tardy JC, Trabaud MA, Ravaux I, Ménard A, Belkhir AY, Colson P, Dhiver C, Madrid A, Martin-Degioanni M, Meddeb L, Mokhtari M, Motte A, Raoux A, Toméi C, Tissot-Dupont H, Poizot-Martin I, Brégigeon S, Zaegel-Faucher O, Obry-Roguet V, Laroche H, Orticoni M, Soavi MJ, Ressiot E, Ducassou MJ, Jaquet I, Galie S, Colson H, Ritleng AS, Ivanova A, Debreux C, Lions C, Rojas-Rojas T, Cabié A, Abel S, Bavay J, Bigeard B, Cabras O, Cuzin L, Dupin de Majoubert R, Fagour L, Guitteaud K, Marquise A, Najioullah F, Pierre-François S, Pasquier J, Richard P, Rome K, Turmel JM, Varache C, Atoui N, Bistoquet M, Delaporte E, Le Moing V, Makinson A, Meftah N, Merle de Boever C, Montes B, Montoya Ferrer A, Tuaillon E, Reynes J, Lefèvre B, Jeanmaire E, Hénard S, Frentiu E, Charmillon A, Legoff A, Tissot N, André M, Boyer L, Bouillon MP, Delestan M, Goehringer F, Bevilacqua S, Rabaud C, May T, Raffi F, Allavena C, Aubry O, Billaud E, Biron C, Bonnet B, Bouchez S, Boutoille D, Brunet-Cartier C, Deschanvres C, Gaborit BJ, Grégoire A, Grégoire M, Grossi O, Guéry R, Jovelin T, Lefebvre M, Le Turnier P, Lecomte R, Morineau P, Reliquet V, Sécher S, Cavellec M, Paredes E, Soria A, Ferré V, André-Garnier E, Rodallec A, Pugliese P, Breaud S, Ceppi C, Chirio D, Cua E, Dellamonica P, Demonchy E, De Monte A, Durant J, Etienne C, Ferrando S, Garraffo R, Michelangeli C, Mondain V, Naqvi A, Oran N, Perbost I, Carles M, Klotz C, Maka A, Pradier C, Prouvost-Keller B, Risso K, Rio V, Rosenthal E, Touitou I, Wehrlen-Pugliese S, Zouzou G, Hocqueloux L, Prazuck T, Gubavu C, Sève A, Giaché S, Rzepecki V, Colin M, Boulard C, Thomas G, Cheret A, Goujard C, Quertainmont Y, Teicher E, Lerolle N, Jaureguiberry S, Colarino R, Deradji O, Castro A, Barrail-Tran A, Yazdanpanah Y, Landman R, Joly V, Ghosn J, Rioux C, Lariven S, Gervais A, Lescure FX, Matheron S, Louni F, Julia Z, Le GAC S, Charpentier C, Descamps D, Peytavin G, Duvivier C, Aguilar C, Alby-Laurent F, Amazzough K, Benabdelmoumen G, Bossi P, Cessot G, Charlier C, Consigny PH, Jidar K, Lafont E, Lanternier F, Leporrier J, Lortholary O, Louisin C, Lourenco J, Parize P, Pilmis B, Rouzaud C, Touam F, Valantin MA, Tubiana R, Agher R, Seang S, Schneider L, PaLich R, Blanc C, Katlama C, Bani-Sadr F, Berger JL, N’Guyen Y, Lambert D, Kmiec I, Hentzien M, Brunet A, Romaru J, Marty H, Brodard V, Arvieux C, Tattevin P, Revest M, Souala F, Baldeyrou M, Patrat-Delon S, Chapplain JM, Benezit F, Dupont M, Poinot M, Maillard A, Pronier C, Lemaitre F, Morlat C, Poisson-Vannier M, Jovelin T, Sinteff JP, Gagneux-Brunon A, Botelho-Nevers E, Frésard A, Ronat V, Lucht F, Rey D, Fischer P, Partisani M, Cheneau C, Priester M, Mélounou C, Bernard-Henry C, de Mautort E, Fafi-Kremer S, Delobel P, Alvarez M, Biezunski N, Debard A, Delpierre C, Gaube G, Lansalot P, Lelièvre L, Marcel M, Martin-Blondel G, Piffaut M, Porte L, Saune K, Robineau O, Ajana F, Aïssi E, Alcaraz I, Alidjinou E, Baclet V, Bocket L, Boucher A, Digumber M, Huleux T, Lafon-Desmurs B, Meybeck A, Pradier M, Tetart M, Thill P, Viget N, Valette M. Microelimination or Not? The Changing Epidemiology of Human Immunodeficiency Virus-Hepatitis C Virus Coinfection in France 2012–2018. Clin Infect Dis 2021; 73:e3266-e3274. [DOI: 10.1093/cid/ciaa1940] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/02/2020] [Accepted: 01/01/2021] [Indexed: 01/15/2023] Open
Abstract
Abstract
Background
The arrival of highly effective, well-tolerated, direct-acting antiviral agents (DAA) led to a dramatic decrease in hepatitis C virus (HCV) prevalence. Human immunodeficiency virus (HIV)-HCV–coinfected patients are deemed a priority population for HCV elimination, while a rise in recently acquired HCV infections in men who have sex with men (MSM) has been described. We describe the variations in HIV-HCV epidemiology in the French Dat’AIDS cohort.
Methods
This was a retrospective analysis of a prospective cohort of persons living with HIV (PLWH) from 2012 to 2018. We determined HCV prevalence, HCV incidence, proportion of viremic patients, treatment uptake, and mortality rate in the full cohort and by HIV risk factors.
Results
From 2012 to 2018, 50 861 PLWH with a known HCV status were followed up. During the period, HCV prevalence decreased from 15.4% to 13.5%. HCV prevalence among new HIV cases increased from 1.9% to 3.5% in MSM but remained stable in other groups. Recently acquired HCV incidence increased from 0.36/100 person-years to 1.25/100 person-years in MSM. The proportion of viremic patients decreased from 67.0% to 8.9%. MSM became the first group of viremic patients in 2018 (37.9%). Recently acquired hepatitis represented 59.2% of viremic MSM in 2018. DAA treatment uptake increased from 11.4% to 61.5%. More treatments were initiated in MSM in 2018 (41.2%) than in intravenous drug users (35.6%). In MSM, treatment at the acute phase represented 30.0% of treatments in 2018.
Conclusions
A major shift in HCV epidemiology was observed in PLWH in France from 2012 to 2018, leading to a unique situation in which the major group of HCV transmission in 2018 was MSM.
Clinical Trials Registration. NCT02898987.
Collapse
Affiliation(s)
- Laurent Cotte
- Department of Infectious Diseases, Croix-Rousse Hospital, Hospices Civils de Lyon, Lyon, Institut National de la Santé et de la Recherche Médicale (INSERM) U1052, Lyon, France
| | - Laurent Hocqueloux
- Department of Infectious Diseases, Centre Hospitalier Régional d’Orléans – La Source, Orléans, France
| | - Maeva Lefebvre
- Department of Infectious Diseases, Centre Hospitalier Universitaire Hôtel-Dieu, Nantes; Centre d’Investigation Clinique (CIC) 1413, INSERM, Nantes, France
| | - Pierre Pradat
- Center for Clinical Research, Croix-Rousse Hospital, Hospices Civils de Lyon, Lyon, France
| | - Firouze Bani-Sadr
- Department of Internal Medicine, Clinical Immunology and Infectious Diseases, Robert Debré Hospital, University Hospital, Reims, France
| | - Thomas Huleux
- Department of Infectious Diseases and Travel Diseases, Centre Hospitalier Gustave-Dron, Tourcoing, France
| | - Isabelle Poizot-Martin
- Immuno-Hematology Clinic, Assistance Publique–Hôpitaux de Marseille, Hôpital Sainte-Marguerite, Marseille, Aix-MarseilleUniversity–Inserm–Institut de Recherche pour le Développement (IRD), Sciences Economiques & Sociales de la Santé & Traitement de l’Information Médicale, Marseille, France
| | - Pascal Pugliese
- Department of Infectious Diseases, Centre Hospitalier Universitaire de Nice, Hôpital l’Archet, Nice, France
| | - David Rey
- HIV Infection Care Centre, Hôpitaux Universitaires, Strasbourg
| | - André Cabié
- Department of Infectious Diseases, Centre Hospitalier Universitaire de Martinique, Fort de France, Université des Antilles EA4537, Fort de France, INSERM CIC1424, Fort-de-France, France
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
6
|
Gagneux-Brunon A, Detoc M, Bruel S, Tardy B, Rozaire O, Frappe P, Botelho-Nevers E. Intention to get vaccinations against COVID-19 in French healthcare workers during the first pandemic wave: a cross-sectional survey. J Hosp Infect 2020; 108:168-173. [PMID: 33259883 PMCID: PMC7699157 DOI: 10.1016/j.jhin.2020.11.020] [Citation(s) in RCA: 349] [Impact Index Per Article: 87.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/20/2020] [Revised: 11/24/2020] [Accepted: 11/25/2020] [Indexed: 01/07/2023]
Abstract
Background Healthcare workers (HCWs) are at the frontline of the COVID-19 pandemic and identified as a priority target group for COVID-19 vaccines. We aimed to determine COVID-19 vaccine acceptance rate in HCWs in France. Methods We conducted an anonymous survey from 26th March to 2nd July 2020. The primary endpoint was the intention to get vaccinated against COVID-19 if a vaccine was available. Results Two-thousand and forty-seven HCWs answered the survey; women accounted for 74% of respondents. Among respondents, 1.554 (76.9%, 95% confidence interval 75.1–78.9) would accept a COVID-19 vaccine. Older age, male gender, fear about COVID-19, individual perceived risk and flu vaccination during previous season were associated with hypothetical COVID-19 vaccine acceptance. Nurses and assistant nurses were less prone to accept vaccination against COVID-19 than physicians. Vaccine hesitancy was associated with a decrease in COVID-19 vaccine acceptance. Flu vaccine rate was 57.3% during the previous season, and 54.6% of the respondents had the intention to get a flu vaccine during the next season. Conclusions Intention to get vaccinated against COVID-19 reached 75% in HCWs with discrepancies between occupational categories. COVID-19 pandemic had no positive effect on flu vaccine acceptance rate.
Collapse
Affiliation(s)
- A Gagneux-Brunon
- Department of Infectious and Tropical Diseases, University Hospital of Saint-Etienne, Saint-Etienne, France; Centre d'investigation Clinique 1408-INSERM, University Hospital of Saint-Etienne, Saint-Etienne, France; Groupe Immunité des Muqueuses et Agents Pathogènes EA3064, University Jean Monnet, Université de Lyon, Saint-Etienne, France; Institut PRESAGE, Chaire Prevention Vaccination et Contrôle de L'Infection, University Jean Monnet, Université de Lyon, Saint-Etienne, France.
| | - M Detoc
- Department of Infectious and Tropical Diseases, University Hospital of Saint-Etienne, Saint-Etienne, France; Centre d'investigation Clinique 1408-INSERM, University Hospital of Saint-Etienne, Saint-Etienne, France
| | - S Bruel
- Department of General Medicine, Faculté de Médecine Jacques Lisfranc, University Jean Monnet, Université de Lyon, Saint-Etienne, France
| | - B Tardy
- Centre d'investigation Clinique 1408-INSERM, University Hospital of Saint-Etienne, Saint-Etienne, France
| | - O Rozaire
- Union Régionale des Professionnels de Santé Pharmaciens, Auvergne Rhône Alpes, France
| | - P Frappe
- Centre d'investigation Clinique 1408-INSERM, University Hospital of Saint-Etienne, Saint-Etienne, France; Department of General Medicine, Faculté de Médecine Jacques Lisfranc, University Jean Monnet, Université de Lyon, Saint-Etienne, France
| | - E Botelho-Nevers
- Department of Infectious and Tropical Diseases, University Hospital of Saint-Etienne, Saint-Etienne, France; Centre d'investigation Clinique 1408-INSERM, University Hospital of Saint-Etienne, Saint-Etienne, France; Groupe Immunité des Muqueuses et Agents Pathogènes EA3064, University Jean Monnet, Université de Lyon, Saint-Etienne, France; Institut PRESAGE, Chaire Prevention Vaccination et Contrôle de L'Infection, University Jean Monnet, Université de Lyon, Saint-Etienne, France
| |
Collapse
|
7
|
Breugnon E, Thollot H, Fraissenon A, Saunier F, Labetoulle R, Pillet S, Lucht F, Berthelot P, Botelho-Nevers E, Gagneux-Brunon A. COVID-19 outpatient management: Shorter time to recovery in Healthcare workers according to an electronic daily symptoms assessment. Infect Dis Now 2020; 51:71-76. [PMID: 33038441 PMCID: PMC7539789 DOI: 10.1016/j.medmal.2020.10.001] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/13/2020] [Revised: 09/04/2020] [Accepted: 10/01/2020] [Indexed: 12/23/2022]
Abstract
Objectives Our aim is to compare the course of the disease between healthcare workers (HCWs) and non-HCWs suffering from covid-19 and eligible for outpatient management. Methods Single-center prospective cohort of outpatients with covid-19, diagnosed between the 10th March and the 2nd April, 2020 with a daily collection of symptoms by an on-line auto-questionnaire. Results A total of 186 patients were included (median age, 41 years [interquartile range, 19–78 years]; 74.2% female), of whom 132 (71%) were HCWs. The median follow-up after symptom onset was 14 (min 4–max 24) days. HCWs were significantly younger than non-HCWs (median age 40.3 years vs. 47.2 years [P < 0.005]), and 81.8% were women. Four patients (2.2%) were hospitalized including one HCW. The median time to recovery was 9 days after symptom onset (95% CI 8-11) in the global population and respectively 8 (95% CI 8–9) and 13 (95% CI 11–15) days in HCWs and in non-HCWs (P < 0.005). After adjusting for age, co-morbidities, and gender, the instantaneous risk ratio for symptom absence in HCWs was 1.76 compared with non-HCWs (95% CI [1.16–2.67], P = 0.037). Conclusion HCWs suffering from covid-19 had favorable outcomes and had a shorter time to recovery than non HCWs.
Collapse
Affiliation(s)
- E Breugnon
- Department of Hygiene and Infectious Diseases, University Hospital of Saint-Etienne, 42055 Saint-Etienne Cedex 2, France
| | - H Thollot
- Department of Public health and biostatistics, University Hospital of Saint-Etienne, Saint-Etienne, France
| | - A Fraissenon
- Department of Radiology, University Hospital of Saint-Etienne, Saint-Etienne, France
| | - F Saunier
- Department of Hygiene and Infectious Diseases, University Hospital of Saint-Etienne, 42055 Saint-Etienne Cedex 2, France
| | - R Labetoulle
- Department of Hygiene and Infectious Diseases, University Hospital of Saint-Etienne, 42055 Saint-Etienne Cedex 2, France
| | - S Pillet
- Laboratory of Microbiology and Hygiene, University Hospital of Saint-Etienne, Saint-Etienne, France; Groupe Immunité des Muqueuses et Agents Pathogènes, Université Jean Monnet, Université de Lyon, Saint-Etienne, France
| | - F Lucht
- Department of Hygiene and Infectious Diseases, University Hospital of Saint-Etienne, 42055 Saint-Etienne Cedex 2, France; Groupe Immunité des Muqueuses et Agents Pathogènes, Université Jean Monnet, Université de Lyon, Saint-Etienne, France; CIC-INSERM 1408, University Hospital of Saint-Etienne, Saint-Etienne, France
| | - P Berthelot
- Department of Hygiene and Infectious Diseases, University Hospital of Saint-Etienne, 42055 Saint-Etienne Cedex 2, France; Groupe Immunité des Muqueuses et Agents Pathogènes, Université Jean Monnet, Université de Lyon, Saint-Etienne, France; CIC-INSERM 1408, University Hospital of Saint-Etienne, Saint-Etienne, France
| | - E Botelho-Nevers
- Department of Hygiene and Infectious Diseases, University Hospital of Saint-Etienne, 42055 Saint-Etienne Cedex 2, France; Groupe Immunité des Muqueuses et Agents Pathogènes, Université Jean Monnet, Université de Lyon, Saint-Etienne, France; CIC-INSERM 1408, University Hospital of Saint-Etienne, Saint-Etienne, France
| | - A Gagneux-Brunon
- Department of Hygiene and Infectious Diseases, University Hospital of Saint-Etienne, 42055 Saint-Etienne Cedex 2, France; Groupe Immunité des Muqueuses et Agents Pathogènes, Université Jean Monnet, Université de Lyon, Saint-Etienne, France; CIC-INSERM 1408, University Hospital of Saint-Etienne, Saint-Etienne, France
| |
Collapse
|
8
|
Breugnon E, Thollot H, Fraissenon A, Saunier F, Labetoulle R, Pillet S, Lucht F, Berthelot P, Botelho-Nevers E, Gagneux-Brunon A. COVID-19 : les soignants sont-ils de véritables super-héros ? Med Mal Infect 2020. [PMCID: PMC7441942 DOI: 10.1016/j.medmal.2020.06.116] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Abstract
Introduction Une grande partie des connaissances en cours concernant la COVID-19 est basée sur les données des patients hospitalisés. Notre objectif est de décrire l’évolution au jour le jour de la COVID-19 dans les cas admissibles à une prise en charge ambulatoire. Matériels et méthodes Cohorte prospective monocentrique de patients présentant une infection par le SARS-CoV-2 confirmée virologiquement et présentant des symptômes modérés, admissibles à une prise en charge ambulatoire, entre le 10 mars et le 2 avril 2020. Les symptômes quotidiens ont été recueillis au moyen d’un auto-questionnaire en ligne. Nous avons considéré qu’un patient était guéri lorsqu’aucun des trois symptômes principaux (fièvre, dyspnée et douleur thoracique) n’était signalé après les derniers symptômes connus via l’application en ligne. Résultats Un total de 186 patients ont été inclus (âge médian, 41 ans [intervalle interquartile, 19–78 ans] ; 74,2 % de femmes), dont 132 (71 %) étaient des professionnels de santé. Treize patients (7 %) souffraient d’hypertension artérielle (la comorbidité la plus courante) et le suivi médian après l’apparition des symptômes était de 14 jours (min 4–max 24). Les professionnels de santé étaient significativement plus jeunes que les autres (âge médian de 40,3 ans contre 47,2 ans [p < 0,005]), et 81,8 % étaient des femmes. Quatre patients (2,2 %) ont été hospitalisés, dont un professionnel de santé. Le délai médian de guérison était de 9 jours après l’apparition des symptômes (IC95 % : 8–11) dans notre population globale et de 8 jours (IC95 % : 8–9) et 13 jours (IC95 % : 11–15) chez les professionnels de santé et les non-professionnels de santé (p < 0,005), respectivement. Après ajustement sur l’âge, le sexe, les comorbidités et le seuil de détection de la PCR SARS-CoV-2, le rapport de risque instantané pour l’absence de symptômes chez les professionnels de santé était de 1,76 par rapport aux non-professionnels de santé (IC95 % [1,16–2,67], p = 0,037). Conclusion La grande majorité de cette cohorte de personnes atteintes d’une infection par la COVID-19 a guéri spontanément. Les professionnels de santé souffrant de la COVID-19 ont eu des résultats favorables et ont eu un temps de récupération plus court que les non-professionnels de santé. Des études supplémentaires sont nécessaires pour mieux comprendre ces différences.
Collapse
|
9
|
Stahl J, Boutoille D, Saidani N, Botelho-Nevers E, Alfandari S, Guimard T, Dinh A, Chavanet P, Longshaw C, Lopes S. Étude CARBAR en France : épidémiologie des pathogènes à Gram négatif. Med Mal Infect 2020. [DOI: 10.1016/j.medmal.2020.06.256] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
10
|
Gousseff M, Botelho-Nevers E, Conrad A, Gallay L, Goehringer F, Lemaignen A, Lescure F, Penot P, Salmon D, Pozzetto B. Récurrences symptomatiques de COVID-19 confirmées après guérison clinique d’un premier épisode : rechute, réinfection ou rebond inflammatoire ? Med Mal Infect 2020. [PMCID: PMC7442014 DOI: 10.1016/j.medmal.2020.06.195] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
Abstract
Introduction Bien que, par analogie aux autres coronavirus, la maladie COVID-19 induite par SARS-CoV-2 ait été initialement supposée monophasique et transitoirement immunisante, de rares publications rapportent des patients avec 2e épisode. L’objectif de cette étude est de décrire les caractéristiques cliniques, la séquence moléculaire de détection virale, et le devenir de patients présentant 2 épisodes distincts de COVID-19. Matériels et méthodes Une étude nationale multicentrique rétrospective observationnelle a recensé les patients présentant un 2e épisode aigu symptomatique de COVID-19, défini par au moins un signe clinique majeur typique, et une PCR SARS-CoV-2 positive dans les voies aériennes, après : – au moins 21 jours du début du 1er épisode ; – une phase de guérison clinique (retour à l’état antérieur, ou sortie de soins aigus sans oxygène), sans diagnostic différentiel infectieux, thromboembolique ou inflammatoire. Résultats Onze patients présentant un 2e épisode de COVID-19 après une guérison clinique médiane [étendue] de 10 [3–27] jours ont été recensés, et 2 groupes ont été individualisés. Dans le 1er, 4 soignants sans comorbidités, d’âge médian 32,5 [19–43] ans, potentiellement re-exposés au SARS-CoV- (3 dans des unités de soins COVID, 1 au domicile), ont présenté aux 2 épisodes une maladie modérée suivie en ambulatoire. Dans le 2e groupe, 7 patients comorbides (dont 2 sous chimiothérapie), d’âges médian 73 [54–91] ans, ont été hospitalisés en soins aigus à chaque épisode. Au 1er, 3 patients ont reçu des corticoïdes. Aucune réexposition au SARS-CoV-2 n’a été documentée, et 3 patients sont décédés, dont 2 de syndrome de détresse respiratoire aiguë sans autre cause que le SARS-CoV-2. Au 2e épisode, tous les scanners montraient des signes aigus de COVID-19, 4/9 PCR avaient des « cycle threshold » (CT) < 30, et 1 sur 2 cultures virales pratiquées était positive. La sérologie SARS-CoV-2 après j21 était positive pour 6 patients, et négative pour 3 (du 2e groupe). Conclusion Cette étude exploratoire confirme la possibilité de récurrences de symptômes après guérison clinique d’un premier épisode de COVID-19. La positivité des PCR aux 2e épisodes (de plusieurs gènes ou avec CT bas) et au moins une culture virale positive, sans diagnostic différentiel identifié, sont en faveur d’une origine virale à ces récurrences. Les caractéristiques des 2 groupes de patients suggèrent soit des réinfections, soit des réactivations virales. Un déficit immunitaire relatif cellulaire ou humoral (par épuisement professionnel ou immuno-senescence, ou traitements immunosuppresseurs), pourraient entraver la clairance virale ou l’efficacité immunitaire antivirale contre les réinfections à SARS-CoV-2. De plus larges études épidémiologiques, et immuno-virologiques sont nécessaires pour comprendre la fréquence et le(s) mécanisme(s) de ces récurrences.
Collapse
|
11
|
Gagneux-Brunon A, Pelissier C, Gagnaire J, Pillet S, Pozzetto B, Botelho-Nevers E, Berthelot P. SARS-CoV-2 infection: advocacy for training and social distancing in healthcare settings. J Hosp Infect 2020; 106:610-612. [PMID: 32781200 PMCID: PMC7414384 DOI: 10.1016/j.jhin.2020.08.001] [Citation(s) in RCA: 16] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/18/2020] [Accepted: 08/03/2020] [Indexed: 11/28/2022]
Abstract
This article reports the observed rate of infection with severe acute respiratory syndrome coronavirus-2 in healthcare workers (HCWs) who worked on wards dedicated to care of patients with coronavirus disease 2019 (COVID-19) compared with HCWs who worked on non-COVID-19 wards. The infection rate was significantly higher among HCWs who worked on non-COVID-19 wards (odds ratio 2.3, P=0.005), illustrating the need to strengthen social distancing measures and training.
Collapse
Affiliation(s)
- A Gagneux-Brunon
- Infection Control Unit, Infectious Diseases Department, University Hospital of Saint-Etienne, Saint-Etienne, France; GIMAP EA 3064 (Groupe Immunité des Muqueuses et Agents Pathogènes), University of Lyon, Université Jean Monnet, Saint-Etienne, France; Institut Presage Université de Lyon, Université Jean Monnet, Saint-Etienne, France
| | - C Pelissier
- Occupational Health Unit, University Hospital of Saint-Etienne, Saint-Etienne, France
| | - J Gagnaire
- Infection Control Unit, Infectious Diseases Department, University Hospital of Saint-Etienne, Saint-Etienne, France
| | - S Pillet
- GIMAP EA 3064 (Groupe Immunité des Muqueuses et Agents Pathogènes), University of Lyon, Université Jean Monnet, Saint-Etienne, France; Service des Agents Infectieux et Hygiène, University Hospital of Saint-Etienne, Saint-Etienne, France
| | - B Pozzetto
- GIMAP EA 3064 (Groupe Immunité des Muqueuses et Agents Pathogènes), University of Lyon, Université Jean Monnet, Saint-Etienne, France; Service des Agents Infectieux et Hygiène, University Hospital of Saint-Etienne, Saint-Etienne, France
| | - E Botelho-Nevers
- Infection Control Unit, Infectious Diseases Department, University Hospital of Saint-Etienne, Saint-Etienne, France; GIMAP EA 3064 (Groupe Immunité des Muqueuses et Agents Pathogènes), University of Lyon, Université Jean Monnet, Saint-Etienne, France; Institut Presage Université de Lyon, Université Jean Monnet, Saint-Etienne, France
| | - P Berthelot
- Infection Control Unit, Infectious Diseases Department, University Hospital of Saint-Etienne, Saint-Etienne, France; GIMAP EA 3064 (Groupe Immunité des Muqueuses et Agents Pathogènes), University of Lyon, Université Jean Monnet, Saint-Etienne, France; Institut Presage Université de Lyon, Université Jean Monnet, Saint-Etienne, France; Service des Agents Infectieux et Hygiène, University Hospital of Saint-Etienne, Saint-Etienne, France.
| |
Collapse
|
12
|
Bruel S, Leclercq T, Ginzarly M, Botelho-Nevers E, Frappé P, Gagneux-Brunon A. Patient decision aid in vaccination: a systematic review of the literature. Expert Rev Vaccines 2020; 19:305-311. [DOI: 10.1080/14760584.2020.1742111] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/08/2023]
Affiliation(s)
- S. Bruel
- Department of General Practice, Jean Monnet University, Saint Etienne, France
- HESPER EA, University of Lyon, Claude Bernard Lyon 1 University, Saint-Etienne University, France
| | - T. Leclercq
- Department of General Practice, Jean Monnet University, Saint Etienne, France
| | - M. Ginzarly
- The Clinic, Dubai International Financial Center, United Arab Emirates
| | - E. Botelho-Nevers
- CIC-INSERM 1408, CHU de Saint-Etienne, France
- Groupe Immunité des Muqueuses et Agents Pathogènes EA 3064, Jean Monnet University, University of Lyon, France
| | - P. Frappé
- Department of General Practice, Jean Monnet University, Saint Etienne, France
| | - A. Gagneux-Brunon
- CIC-INSERM 1408, CHU de Saint-Etienne, France
- Groupe Immunité des Muqueuses et Agents Pathogènes EA 3064, Jean Monnet University, University of Lyon, France
| |
Collapse
|
13
|
Raia-Barjat T, Gannard I, Virieux D, Del Aguila-Berthelot C, Nekaa M, Chauvin F, Botelho-Nevers E, Berthelot P, Gagneux-Brunon A. Health students' knowledge of sexually transmitted infections and risky behaviors before participation to the health promotion program. Med Mal Infect 2020; 50:368-371. [PMID: 32067796 DOI: 10.1016/j.medmal.2020.01.015] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/14/2019] [Revised: 11/26/2019] [Accepted: 01/30/2020] [Indexed: 10/25/2022]
Abstract
OBJECTIVES We aimed to evaluate knowledge of health students (HS) enrolled in a health promotion program about sexually transmitted infections (STIs) and the frequency of risky behaviors. METHODS HS answered two anonymous questionnaires, a mandatory one about knowledge of STIs and STI prevention and an optional one about behaviors. RESULTS Two-hundred and sixteen HS answered the first questionnaire and 183 answered the second one. Eighty-three percent of HS had a good knowledge of HIV transmission, but half of them were aware of pre-exposure and post-exposure prophylaxes for HIV. The role of HPV infection in genital warts and anal cancer was respectively known by 33 (15.3%) and 10 (4.6%) HS. Thirty-six HS (19.7%) reported having unprotected sex in the previous 12 months. CONCLUSION French HS had a poor knowledge of STIs and STI prevention, and risky behaviors. It is necessary to provide good training on STIs to HS.
Collapse
Affiliation(s)
- T Raia-Barjat
- Service de gynécologie-obstétrique, CHU de Saint-Étienne, Saint-Étienne, France
| | - I Gannard
- IFSI hôpital du Gier, Saint-Chamond, France
| | - D Virieux
- Service d'infectiologie, CHU de Saint-Étienne, Saint-Étienne, France
| | | | - M Nekaa
- Académie de Lyon, Saint-Étienne, France
| | - F Chauvin
- Centre Hygée, Saint-Priest-en-Jarez, France; Institut de prévention en santé globale Présage, université de Lyon, UJM, Lyon, France
| | - E Botelho-Nevers
- Service d'infectiologie, CHU de Saint-Étienne, Saint-Étienne, France; Institut de prévention en santé globale Présage, université de Lyon, UJM, Lyon, France
| | - P Berthelot
- Service d'infectiologie, CHU de Saint-Étienne, Saint-Étienne, France; Institut de prévention en santé globale Présage, université de Lyon, UJM, Lyon, France
| | - A Gagneux-Brunon
- Service d'infectiologie, CHU de Saint-Étienne, Saint-Étienne, France; Institut de prévention en santé globale Présage, université de Lyon, UJM, Lyon, France.
| |
Collapse
|
14
|
Chazot R, Botelho-Nevers E, Fresard A, Lucht F, Mariat C, Maillard N, Gagneux-Brunon A. Chronic kidney disease is highly prevalent in people living with HIV in a mainly Caucasian European cohort. HIV Med 2019; 21:e8-e9. [PMID: 31852018 DOI: 10.1111/hiv.12827] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Affiliation(s)
- R Chazot
- Department of Nephrology, Dialysis and Transplantation, University Hospital of Saint-Etienne, Saint-Etienne, France
| | - E Botelho-Nevers
- Department of Infectious and Tropical Diseases, University Hospital of Saint-Etienne, Saint-Etienne, France
| | - A Fresard
- Department of Infectious and Tropical Diseases, University Hospital of Saint-Etienne, Saint-Etienne, France
| | - F Lucht
- Department of Infectious and Tropical Diseases, University Hospital of Saint-Etienne, Saint-Etienne, France
| | - C Mariat
- Department of Nephrology, Dialysis and Transplantation, University Hospital of Saint-Etienne, Saint-Etienne, France
| | - N Maillard
- Department of Nephrology, Dialysis and Transplantation, University Hospital of Saint-Etienne, Saint-Etienne, France
| | - A Gagneux-Brunon
- Department of Infectious and Tropical Diseases, University Hospital of Saint-Etienne, Saint-Etienne, France
| |
Collapse
|
15
|
Rigaill J, Morgene MF, Gavid M, Lelonge Y, He Z, Carricajo A, Grattard F, Pozzetto B, Berthelot P, Botelho-Nevers E, Verhoeven PO. Intracellular activity of antimicrobial compounds used for Staphylococcus aureus nasal decolonization. J Antimicrob Chemother 2019; 73:3044-3048. [PMID: 30124897 DOI: 10.1093/jac/dky318] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/24/2018] [Accepted: 07/11/2018] [Indexed: 01/04/2023] Open
Abstract
Background Staphylococcus aureus is able to invade mammalian cells during infection and was recently observed inside nasal mucosa of healthy carriers. Objectives To determine the intracellular activity of antimicrobial compounds used for decolonization procedures using a cell model mimicking S. aureus nasal epithelium invasion. Patients and methods HaCaT cells and human nasal epithelial cells (HNECs) recovered from nasal swabs of S. aureus carriers were visualized by confocal laser scanning microscopy to detect intracellular S. aureus cells. An HaCaT cell model, mimicking S. aureus internalization observed ex vivo in HNECs, was used to assess the intracellular activity against S. aureus of 21 antimicrobial compounds used for nasal decolonization, including mupirocin and chlorhexidine. Results HaCaT cells and HNECs were found to internalize S. aureus with the same focal pattern. Most antimicrobial compounds tested on HaCaT cells were shown to have weak activity against intracellular S. aureus. Some systemic antimicrobials, including fusidic acid, clindamycin, linezolid, minocycline, ciprofloxacin, moxifloxacin, rifampicin and levofloxacin, reduced S. aureus intracellular loads by 0.43-1.66 log cfu/106 cells compared with the control (P < 0.001). By contrast, mupirocin and chlorhexidine reduced the S. aureus intracellular load by 0.19 and 0.23 log cfu/106 cells, respectively. Conclusions These data indicate that most of the antimicrobial compounds used for nasal decolonization, including mupirocin and chlorhexidine, exhibit weak activity against intracellular S. aureus using the HaCaT cell model. This work emphasizes the need to better understand the role of the S. aureus intracellular reservoir during nasal colonization in order to improve decolonization procedures.
Collapse
Affiliation(s)
- J Rigaill
- Group for Mucosal Immunity and Pathogen Agents (GIMAP), EA 3064, University of Lyon, St-Etienne, France.,Laboratory of Infectious Agents and Hygiene, University Hospital of St-Etienne, St-Etienne cedex 02, France
| | - M F Morgene
- Laboratory of Infectious Agents and Hygiene, University Hospital of St-Etienne, St-Etienne cedex 02, France
| | - M Gavid
- Department of Ear Nose Throat Surgery, University Hospital of St-Etienne, St-Etienne cedex 02, France
| | - Y Lelonge
- Department of Ear Nose Throat Surgery, University Hospital of St-Etienne, St-Etienne cedex 02, France
| | - Z He
- Corneal Graft Biology, Engineering and Imaging Laboratory (BiiGC), EA2521, University of Lyon, St-Etienne, France
| | - A Carricajo
- Group for Mucosal Immunity and Pathogen Agents (GIMAP), EA 3064, University of Lyon, St-Etienne, France.,Laboratory of Infectious Agents and Hygiene, University Hospital of St-Etienne, St-Etienne cedex 02, France
| | - F Grattard
- Group for Mucosal Immunity and Pathogen Agents (GIMAP), EA 3064, University of Lyon, St-Etienne, France.,Laboratory of Infectious Agents and Hygiene, University Hospital of St-Etienne, St-Etienne cedex 02, France
| | - B Pozzetto
- Group for Mucosal Immunity and Pathogen Agents (GIMAP), EA 3064, University of Lyon, St-Etienne, France.,Laboratory of Infectious Agents and Hygiene, University Hospital of St-Etienne, St-Etienne cedex 02, France
| | - P Berthelot
- Group for Mucosal Immunity and Pathogen Agents (GIMAP), EA 3064, University of Lyon, St-Etienne, France.,Department of Infectious Diseases, University Hospital of St-Etienne, St-Etienne cedex 02, France
| | - E Botelho-Nevers
- Group for Mucosal Immunity and Pathogen Agents (GIMAP), EA 3064, University of Lyon, St-Etienne, France.,Department of Infectious Diseases, University Hospital of St-Etienne, St-Etienne cedex 02, France
| | - P O Verhoeven
- Group for Mucosal Immunity and Pathogen Agents (GIMAP), EA 3064, University of Lyon, St-Etienne, France.,Laboratory of Infectious Agents and Hygiene, University Hospital of St-Etienne, St-Etienne cedex 02, France
| |
Collapse
|
16
|
Detoc M, Launay O, Dualé C, Mutter C, Le Huec JC, Lenzi N, Lucht F, Gagneux-Brunon A, Botelho-Nevers E. Barriers and motivations for participation in preventive vaccine clinical trials: Experience of 5 clinical research sites. Vaccine 2019; 37:6633-6639. [PMID: 31543417 DOI: 10.1016/j.vaccine.2019.09.048] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/07/2019] [Revised: 09/10/2019] [Accepted: 09/11/2019] [Indexed: 01/09/2023]
Abstract
Recruitment in preventive vaccine trials (PVT) is challenging due to common barriers to clinical research and lack of vaccine confidence. Identifying determinants of participation can help to improve recruitment. A prospective survey was conducted in 5 French clinical investigational sites. People asked to participate in a PVT were given a questionnaire whether they decided to participate or not in the trial. A total of 341 people answered the survey: 210 accepting and 131 declining to participate in a PVT. Acceptors were significantly younger (38.5 vs 54.9 years old), more likely to be involved in early phase trials, had a higher level of education (p < 0.005) and a significantly better general opinion concerning vaccines (92.3% versus 72.3%, p < 0.005) compared with those who declined. Factors associated with acceptance or refusal were evaluated in 224 people in the 4 sites where both groups were included. In a multivariate analysis, three factors: older age, having heard about PVT through multiple sources and financial incentives were significantly associated with refusal to participate in the PVT. A generally favourable opinion of vaccines was associated with acceptance. The main motivation for participation was altruism (93.2%) whereas fear of side effects was at the forefront of the barriers (36.6%). Information given by the physician was a key point for decision-making in 70.2% of those who accepted. In brief, vaccine hesitancy may decrease recruitment in PVTs; reinforcing altruism and quality of information given are key points in acceptance of participation in PVT.
Collapse
Affiliation(s)
- M Detoc
- Clinical Trial Center, INSERM CIC 1408, University Hospital of Saint-Etienne, 42055 Saint-Etienne, France; Groupe Immunité Muqueuse et Agents Pathogènes (GIMAP), EA3064 - Medical School of Saint-Etienne, University of Lyon, France; Inserm, F-CRIN, Innovative Clinical Research Network in Vaccinology (I-REIVAC), Paris, France
| | - O Launay
- Inserm, F-CRIN, Innovative Clinical Research Network in Vaccinology (I-REIVAC), Paris, France; Université Paris Descartes, Sorbonne Paris Cité, France; Inserm, CIC 1417, Assistance Publique-Hôpitaux de Paris, CIC Cochin Pasteur, Hôpital Cochin Broca Hôtel-Dieu, Paris, France
| | - C Dualé
- Inserm, F-CRIN, Innovative Clinical Research Network in Vaccinology (I-REIVAC), Paris, France; Centre de Pharmacologie Clinique (INSERM CIC1405), CHU Clermont-Ferrand, Clermont-Ferrand, France
| | - C Mutter
- Inserm, F-CRIN, Innovative Clinical Research Network in Vaccinology (I-REIVAC), Paris, France; CIC Inserm 1434, CHU de Strasbourg, Strasbourg, France
| | - J-C Le Huec
- Polyclinique Bordeaux Nord Aquitaine, Unité Rachis, Université Bordeaux Deterca Lab, 15 rue Boucher, 33000 Bordeaux, France
| | - N Lenzi
- Inserm, F-CRIN, Innovative Clinical Research Network in Vaccinology (I-REIVAC), Paris, France
| | - F Lucht
- Clinical Trial Center, INSERM CIC 1408, University Hospital of Saint-Etienne, 42055 Saint-Etienne, France; Groupe Immunité Muqueuse et Agents Pathogènes (GIMAP), EA3064 - Medical School of Saint-Etienne, University of Lyon, France; Inserm, F-CRIN, Innovative Clinical Research Network in Vaccinology (I-REIVAC), Paris, France
| | - A Gagneux-Brunon
- Clinical Trial Center, INSERM CIC 1408, University Hospital of Saint-Etienne, 42055 Saint-Etienne, France; Groupe Immunité Muqueuse et Agents Pathogènes (GIMAP), EA3064 - Medical School of Saint-Etienne, University of Lyon, France; Inserm, F-CRIN, Innovative Clinical Research Network in Vaccinology (I-REIVAC), Paris, France
| | - E Botelho-Nevers
- Clinical Trial Center, INSERM CIC 1408, University Hospital of Saint-Etienne, 42055 Saint-Etienne, France; Groupe Immunité Muqueuse et Agents Pathogènes (GIMAP), EA3064 - Medical School of Saint-Etienne, University of Lyon, France; Inserm, F-CRIN, Innovative Clinical Research Network in Vaccinology (I-REIVAC), Paris, France.
| |
Collapse
|
17
|
Breugnon E, Graouch S, Solvar L, Schein F, Charles R, Guglielminotti C, Poizat B, Gagneux-Brunon A, Botelho-Nevers E. Prévention vaccinale des infections sexuellement transmissibles (IST) : connaissances et méconnaissances des consultants en CeGIDD et au planning familial. Med Mal Infect 2019. [DOI: 10.1016/j.medmal.2019.04.329] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
18
|
Gagneux-Brunon A, Gannard I, Berthelot-Del Aguila C, Virieux D, Barjat T, Botelho-Nevers E. Connaissances et attitudes des étudiants en santé du service sanitaire sur la prévention des Infections Sexuellement Transmissibles, de la nécessaire formation de ces futurs « Préventeurs ». Med Mal Infect 2019. [DOI: 10.1016/j.medmal.2019.04.194] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
19
|
Tamisier N, Maillard N, Brunel P, Roussel M, Botelho-Nevers E, Gagneux-Brunon A. Incidence de la cristallurie à l’amoxicilline dans le traitement des endocardites infectieuses (EI) en 2018 au sein d’un CHU. Med Mal Infect 2019. [DOI: 10.1016/j.medmal.2019.04.149] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
20
|
Vaissière E, Botelho-Nevers E, Pillet S, Cazorla C, Lefèvre M, Chapelle M, Grard G, Mailles A. Encéphalite à tiques : enquête autour des premiers cas d’acquisition locale dans le massif du Livradois-Forez. Med Mal Infect 2019. [DOI: 10.1016/j.medmal.2019.04.379] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
21
|
Vergnon-Miszczycha D, Schein F, Verhoeven P, Fresard A, Cazorla C, Lucht F, Daoud F, Gagneux-Brunon A, Botelho-Nevers E. Facteurs de risque de portage nasal persistant de Staphylococcus aureus dans une cohorte de patients vivant avec le VIH. Med Mal Infect 2019. [DOI: 10.1016/j.medmal.2019.04.365] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
22
|
Schein F, Graouch S, Solvar L, Breugnon E, Guglielminotti C, Poizat B, Gagneux-Brunon A, Botelho-Nevers E. Connaissances des modes de transmission et de prévention non vaccinale des infections sexuellement transmissibles chez les consultants en CeGIDD et planning familial. Med Mal Infect 2019. [DOI: 10.1016/j.medmal.2019.04.099] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
23
|
Perrin-Jourjon A, Mazenod C, Soubeyrand J, Alus S, Maillon R, Delaveau C, Keunebroek J, Berthelot P, Gagneux-Brunon A, Botelho-Nevers E. Recherche clinique en infectiologie et infirmier.e.s : vers une meilleure formation et information pour plus d’implication. Med Mal Infect 2019. [DOI: 10.1016/j.medmal.2019.04.005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
24
|
Lebrun C, Vukusic S, Abadie V, Achour C, Ader F, Alchaar H, Alkhedr A, Andreux F, Androdias G, Arjmand R, Audoin B, Audry D, Aufauvre D, Autreaux C, Ayrignac X, Bailbe M, Benazet M, Bensa C, Bensmail D, Berger E, Bernady P, Bertagna Y, Biotti D, Blanchard-Dauphin A, Bonenfant J, Bonnan M, Bonnemain B, Borgel F, Botelho-Nevers E, Boucly S, Bourre B, Boutière C, Branger P, Brassat D, Bresch S, Breuil V, Brochet B, Brugeilles H, Bugnon P, Cabre P, Camdessanché JP, Carra-Dalière C, Casez O, Chamouard JM, Chassande B, Chataignier P, Chbicheb M, Chenet A, Ciron J, Clavelou P, Cohen M, Colamarino R, Collongues N, Coman I, Corail PR, Courtois S, Coustans M, Creange A, Creisson E, Daluzeau N, Davenas C, De Seze J, Debouverie M, Depaz R, Derache N, Divio L, Douay X, Dulau C, Durand-Dubief F, Edan G, Elias Z, Fagniez O, Faucher M, Faucheux JM, Fournier M, Gagneux-Brunon A, Gaida P, Galli P, Gallien P, Gaudelus J, Gault D, Gayou A, Genevray M, Gentil A, Gere J, Gignoux L, Giroux M, Givron P, Gout O, Grimaud J, Guennoc AM, Hadhoum N, Hautecoeur P, Heinzlef O, Jaeger M, Jeannin S, Kremer L, Kwiatkowski A, Labauge P, Labeyrie C, Lachaud S, Laffont I, Lanctin-Garcia C, Lannoy J, Lanotte L, Laplaud D, Latombe D, Lauxerois M, Le Page E, Lebrun-Frenay C, Lejeune P, Lejoyeux P, Lemonnier B, Leray E, Loche CM, Louapre C, Lubetzki C, Maarouf A, Mada B, Magy L, Maillart E, Manchon E, Marignier R, Marque P, Mathey G, Maurousset A, Mekies C, Merienne M, Michel L, Milor AM, Moisset X, Montcuquet A, Moreau T, Morel N, Moussa M, Naudillon JP, Normand M, Olive P, Ouallet JC, Outteryck O, Pacault C, Papeix C, Patry I, Peaureaux D, Pelletier J, Pichon B, Pittion S, Planque E, Pouget MC, Pourcher V, Radot C, Robert I, Rocher F, Ruet A, Ruet A, Saint-Val C, Salle JY, Salmon A, Sartori E, Schaeffer S, Stankhof B, Taithe F, Thouvenot E, Tizon C, Tourbah A, Tourniaire P, Vaillant M, Vermersch P, Vidil S, Wahab A, Warter MH, Wiertlewski S, Wiplosz B, Wittwer B, Zaenker C, Zephir H. Immunization and multiple sclerosis: Recommendations from the French Multiple Sclerosis Society. Rev Neurol (Paris) 2019; 175:341-357. [DOI: 10.1016/j.neurol.2019.04.001] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/30/2019] [Revised: 03/31/2019] [Accepted: 04/11/2019] [Indexed: 10/26/2022]
|
25
|
Bataillard M, Célarier T, Cathebras P, Lucht F, Berthelot P, Gagneux-Brunon A, Botelho-Nevers E. Vaccination des soignants contre la grippe saisonnière : travailler en gériatrie pas toujours une motivation supplémentaire. Med Mal Infect 2019. [DOI: 10.1016/j.medmal.2019.04.316] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
26
|
Gagneux-Brunon A, Pouvaret A, Maillard N, Berthelot P, Lutz MF, Cazorla C, Tulane C, Fuzellier JF, Verhoeven PO, Frésard A, Duval X, Lucht F, Botelho-Nevers E. Acute kidney injury in infective endocarditis: A retrospective analysis. Med Mal Infect 2019; 49:527-533. [PMID: 30955847 DOI: 10.1016/j.medmal.2019.03.015] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/12/2018] [Revised: 07/26/2018] [Accepted: 03/18/2019] [Indexed: 12/12/2022]
Abstract
BACKGROUND Acute kidney injury (AKI) is associated with high case fatality in infective endocarditis (IE), but epidemiological data on the frequency of AKI during IE is scarce. We aimed to describe the frequency and risk factors for AKI during the course of IE using Kidney Disease: Improving Global Outcomes consensual criteria. METHODS Using the French hospital discharge database (French acronym PMSI), we retrospectively reviewed the charts of 112 patients presenting with a first episode of probable or definite IE between January 2010 and May 2015. RESULTS Seventy-seven patients (68.8%) developed AKI. In univariate analysis, risk factors for AKI were cardiac surgery for IE (n=29, 37.7% vs. n=4, 1.4%, P<0.0005), cardiac failure (n=29, 36.7% vs. n=1, 2.9%, P<0.0005), diabetes mellitus (n=14, 18.2% vs. n=1, 0.9%, P=0.034), and prosthetic valve IEs (n=24, 31.2% vs. n=4, 11.4%). No differences were observed for gentamicin exposure (n=57, 64% vs. n=32, 86.5%, P=0.286). Prosthetic valve IE, cardiac failure, and vancomycin exposure were independently associated with AKI with respective odds ratio of 5.49 (95% CI 1.92-17.9), 4.37 (95% CI 4.37-465.7), and 1.084 (1.084-16.2). Mean length of hospital stay was significantly longer in patients presenting with AKI than in controls (respectively 52.4±22.1 days vs. 39.6±12.6, P<0.005). CONCLUSION AKI is very frequent during IE, particularly in patients with prosthetic valve IE, cardiac failure, and those receiving vancomycin.
Collapse
Affiliation(s)
- A Gagneux-Brunon
- Department of Infectious Diseases, University Hospital of Saint-Etienne, 42055 Saint-Etienne, France; EA 3064, GIMAP, Jean-Monnet University, University of Lyon, 42000 Saint-Etienne, France; CIC 1408 Inserm, 42055 Saint-Etienne, France.
| | - A Pouvaret
- Department of Infectious Diseases, University Hospital of Saint-Etienne, 42055 Saint-Etienne, France
| | - N Maillard
- EA 3064, GIMAP, Jean-Monnet University, University of Lyon, 42000 Saint-Etienne, France; Department of Nephrology, Dialysis, Transplantation and Hypertension, University Hospital of Saint-Etienne, 42055 Saint-Etienne, France
| | - P Berthelot
- Department of Infectious Diseases, University Hospital of Saint-Etienne, 42055 Saint-Etienne, France; EA 3064, GIMAP, Jean-Monnet University, University of Lyon, 42000 Saint-Etienne, France; Laboratory of Microbiology and Hygiene, University Hospital of Saint-Etienne, 42055 Saint-Etienne, France; Infection Control Unit, University Hospital of Saint-Etienne, 42055 Saint-Etienne, France
| | - M F Lutz
- Department of Infectious Diseases, University Hospital of Saint-Etienne, 42055 Saint-Etienne, France; CIC 1408 Inserm, 42055 Saint-Etienne, France
| | - C Cazorla
- Department of Infectious Diseases, University Hospital of Saint-Etienne, 42055 Saint-Etienne, France; CIC 1408 Inserm, 42055 Saint-Etienne, France
| | - C Tulane
- Department of Cardiology, University Hospital of Saint-Etienne, 42055 Saint-Etienne, France
| | - J F Fuzellier
- Department of Cardiac Surgery, University Hospital of Saint-Etienne, 42055 Saint-Etienne, France
| | - P O Verhoeven
- Department of Infectious Diseases, University Hospital of Saint-Etienne, 42055 Saint-Etienne, France; EA 3064, GIMAP, Jean-Monnet University, University of Lyon, 42000 Saint-Etienne, France; Laboratory of Microbiology and Hygiene, University Hospital of Saint-Etienne, 42055 Saint-Etienne, France
| | - A Frésard
- Department of Infectious Diseases, University Hospital of Saint-Etienne, 42055 Saint-Etienne, France; CIC 1408 Inserm, 42055 Saint-Etienne, France
| | - X Duval
- Inserm 1425, Inserm U1137, Centre d'Investigation Clinique, Université Paris-Diderot, Hôpital Bichat, AP-HP, 75018 Paris, France
| | - F Lucht
- Department of Infectious Diseases, University Hospital of Saint-Etienne, 42055 Saint-Etienne, France; EA 3064, GIMAP, Jean-Monnet University, University of Lyon, 42000 Saint-Etienne, France; CIC 1408 Inserm, 42055 Saint-Etienne, France
| | - E Botelho-Nevers
- Department of Infectious Diseases, University Hospital of Saint-Etienne, 42055 Saint-Etienne, France; EA 3064, GIMAP, Jean-Monnet University, University of Lyon, 42000 Saint-Etienne, France; CIC 1408 Inserm, 42055 Saint-Etienne, France
| |
Collapse
|
27
|
Aba YT, Gagneux-Brunon A, Andrillat C, Fouilloux P, Daoud F, Defontaine C, Lucht F, Botelho-Nevers E. Travel medicine consultation: An opportunity to improve coverage for routine vaccinations. Med Mal Infect 2018; 49:257-263. [PMID: 30583868 DOI: 10.1016/j.medmal.2018.11.008] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/12/2017] [Revised: 03/05/2018] [Accepted: 11/20/2018] [Indexed: 11/25/2022]
Abstract
BACKGROUND Travelers may be responsible for the spread of vaccine-preventable diseases upon return. Travel physicians and family physicians may play a role in checking and updating vaccinations before traveling. Our aim was to evaluate the vaccine coverage for mandatory and recommended vaccination in travelers attending a travel medicine clinic (TMC). METHODS Vaccine coverage was measured using the current French immunization schedule as reference for correct immunization, in travelers providing a vaccination certificate during the TMC visit (university hospital of Saint-Étienne), between August 1, 2013 and July 31, 2014. RESULTS In total, 2336 travelers came to the TMC during the study period. Among the 2019 study participants, only 1216 (60.3%) provided a vaccination certificate. Travelers who provided a vaccination certificate were significantly younger than travelers who did not (mean age: 34.8±17.8 vs. 46±18.4 years, P<0.005) and were less likely to be Hajj pilgrims. Vaccine coverage against Tetanus, Diphtheria, and Poliomyelitis (Td/IPV vaccine) was 91.8%, 78.6% against Measles, Mumps, and Rubella (MMR), and 59.4% against Viral Hepatitis B (HBV). BCG vaccine coverage was 71.9%. Older travelers were less likely to be correctly vaccinated, except against HBV as vaccinated travelers were significantly older than unvaccinated travelers. CONCLUSION Obtaining information about immunization in travelers is difficult. Coverage for routine vaccines should be improved in this population. Travel medicine consultations could be the opportunity to vaccinate against MMR, HBV, and Td/IPV.
Collapse
Affiliation(s)
- Y T Aba
- Service des maladies infectieuses et tropicales, Centre de vaccinations internationales et conseils aux voyageurs, CHU de Saint-Étienne, 42055 Saint-Étienne, France; Service de santé publique et de maladies infectieuses, université Alassane Ouattara, Bouaké, Côte d'Ivoire; Groupe immunité des muqueuses et agents Pathogènes - GIMAP EA 3064, université de Saint-Étienne, Université de Lyon, 42270 Saint-Priest-en-Jarez, France
| | - A Gagneux-Brunon
- Service des maladies infectieuses et tropicales, Centre de vaccinations internationales et conseils aux voyageurs, CHU de Saint-Étienne, 42055 Saint-Étienne, France; Inserm, CIC 1408, 42055 Saint-Étienne, France; Inserm, F-CRIN, Innovative clinical research network in vaccinology (I-REIVAC), 75679 Paris, France; Groupe immunité des muqueuses et agents Pathogènes - GIMAP EA 3064, université de Saint-Étienne, Université de Lyon, 42270 Saint-Priest-en-Jarez, France.
| | - C Andrillat
- Service des maladies infectieuses et tropicales, Centre de vaccinations internationales et conseils aux voyageurs, CHU de Saint-Étienne, 42055 Saint-Étienne, France
| | - P Fouilloux
- Service des maladies infectieuses et tropicales, Centre de vaccinations internationales et conseils aux voyageurs, CHU de Saint-Étienne, 42055 Saint-Étienne, France; Inserm, CIC 1408, 42055 Saint-Étienne, France; Inserm, F-CRIN, Innovative clinical research network in vaccinology (I-REIVAC), 75679 Paris, France
| | - F Daoud
- Service des maladies infectieuses et tropicales, Centre de vaccinations internationales et conseils aux voyageurs, CHU de Saint-Étienne, 42055 Saint-Étienne, France
| | - C Defontaine
- Service des maladies infectieuses et tropicales, Centre de vaccinations internationales et conseils aux voyageurs, CHU de Saint-Étienne, 42055 Saint-Étienne, France
| | - F Lucht
- Service des maladies infectieuses et tropicales, Centre de vaccinations internationales et conseils aux voyageurs, CHU de Saint-Étienne, 42055 Saint-Étienne, France; Inserm, CIC 1408, 42055 Saint-Étienne, France; Inserm, F-CRIN, Innovative clinical research network in vaccinology (I-REIVAC), 75679 Paris, France; Groupe immunité des muqueuses et agents Pathogènes - GIMAP EA 3064, université de Saint-Étienne, Université de Lyon, 42270 Saint-Priest-en-Jarez, France
| | - E Botelho-Nevers
- Service des maladies infectieuses et tropicales, Centre de vaccinations internationales et conseils aux voyageurs, CHU de Saint-Étienne, 42055 Saint-Étienne, France; Inserm, CIC 1408, 42055 Saint-Étienne, France; Inserm, F-CRIN, Innovative clinical research network in vaccinology (I-REIVAC), 75679 Paris, France; Groupe immunité des muqueuses et agents Pathogènes - GIMAP EA 3064, université de Saint-Étienne, Université de Lyon, 42270 Saint-Priest-en-Jarez, France
| |
Collapse
|
28
|
Lesens O, Ferry T, Forestier E, Botelho-Nevers E, Pavese P, Piet E, Pereira B, Montbarbon E, Boyer B, Lustig S, Descamps S. Should we expand the indications for the DAIR (debridement, antibiotic therapy, and implant retention) procedure for Staphylococcus aureus prosthetic joint infections? A multicenter retrospective study. Eur J Clin Microbiol Infect Dis 2018; 37:1949-1956. [PMID: 30083889 DOI: 10.1007/s10096-018-3330-7] [Citation(s) in RCA: 18] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/16/2018] [Accepted: 07/16/2018] [Indexed: 12/31/2022]
Abstract
To evaluate factors associated with failure in patients treated with DAIR (debridement, antibiotic therapy, and implant retention) for Staphylococcus aureus prosthetic joint infections (PJIs). We retrospectively analyzed consecutive patients with stable PJI due to S. aureus treated with DAIR at six hospitals between 2010 and 2014. Cox proportional hazards regression was used to study factors associated with treatment failure at 2 years. Of 154 eligible patients, 137 were included (mean age 73 ± 13 years; male 56%). The estimated success rate according to the Kaplan-Meier method was 76.2 [95% CI 68-83] at 2 years of follow-up. In multivariate analysis, longer duration of treatment (hazard ratio (HR) 0.78 [0.69-0.88]; p < 0.001) and combination therapy including rifampin (HR 0.08 [0.018-0.36]; p = 0.001) were independently associated with success, whereas active smoking was independently associated with failure (HR 3.6 [1.09-11.84]; p = 0.036). When the analysis was restricted to patients with early infection onset (< 3 months), early acute infection was also predictive of a better prognosis (HR 0.25 [0.09-0.7]; p = 0.009). Failure was not associated with time from prosthesis insertion to debridement, nor with duration of symptoms > 3 weeks and type of prosthesis (hip or knee). These results remained unchanged when the 14 patients under immunosuppressive therapy were removed from analysis. These data suggest that DAIR can be performed even if infection and symptoms are delayed but reserved to patients who are able to follow rifampin-based combination therapy for a prolonged duration that should not be different for hip and knee PJI.
Collapse
Affiliation(s)
- O Lesens
- Service des Maladies Infectieuses et Tropicales, Hôpital Gabriel Montpied, CRIOAc, CHU, Clermont-Ferrand, France.
- Laboratoire Microorganismes: Génome Environnement (LMGE) UMR 6023, Université Clermont Auvergne, Clermont-Ferrand, France.
| | - T Ferry
- Hospices Civils de Lyon, CRIOAc Lyon, Université Claude Bernard Lyon 1, Villeurbanne, France
| | - E Forestier
- Service de Maladies Infectieuses, CH Métropole Savoie, Chambéry, France
| | - E Botelho-Nevers
- Service d'Infectiologie, CIC1408-Inserm, CRIOAc Saint-Etienne, Hôpital Nord-CHU Saint Etienne, 42055, Saint-Etienne, France
| | - P Pavese
- Service de Maladies Infectieuses, CHU Grenoble Alpes, Grenoble, France
| | - E Piet
- Service d'Infectiologie, CH Annecy Genevois, 74000, Annecy, France
| | - B Pereira
- CHU Clermont-Ferrand, DRCI-Biostatistique, Clermont-Ferrand, France
| | - E Montbarbon
- Service d'Orthopédie-Traumatologie, CH Metropole Savoie, Chambéry, France
| | - B Boyer
- Service Orthopédie, CRIOAc Saint-Etienne, Hôpital Nord-CHU Saint-Etienne, Saint-Etienne, France
| | - S Lustig
- Hospices Civils de Lyon, CRIOAc Lyon, Université Claude Bernard Lyon 1, Villeurbanne, France
| | - S Descamps
- Université Clermont- Auvergne, CHU Clermont-Ferrand, CNRS, SIGMA Clermont, ICCF, 63000, Clermont-Ferrand, France
- Institut de Chimie de Clermont-Ferrand (ICCF), UMR 6296, 24, avenue Blaise-Pascal, 63178, Aubiere, France
| |
Collapse
|
29
|
Schein F, Fouillet L, Lutz MF, Daguenet E, Botelho-Nevers E, Cornillon J. Recurrent Enterococcus faecalis meningitis in a patient presenting with Strongyloides hyperinfection syndrome during HTLV-1-induced T-cell lymphoma. Med Mal Infect 2018; 48:428-430. [PMID: 29884325 DOI: 10.1016/j.medmal.2018.04.389] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/11/2018] [Revised: 03/05/2018] [Accepted: 04/06/2018] [Indexed: 10/14/2022]
Affiliation(s)
- F Schein
- Département d'hématologie clinique, institut de cancérologie Lucien-Neuwirth, 108 bis, avenue A.-Raimond, 42271 Saint-Priest-en-Jarez, France
| | - L Fouillet
- Département d'hématologie clinique, institut de cancérologie Lucien-Neuwirth, 108 bis, avenue A.-Raimond, 42271 Saint-Priest-en-Jarez, France
| | - M F Lutz
- Service des maladies infectieuses et tropicales, CHU de Saint-Étienne, 108, avenue Albert-Raimond, 42271 St-Priest, France
| | - E Daguenet
- Département d'hématologie clinique, institut de cancérologie Lucien-Neuwirth, 108 bis, avenue A.-Raimond, 42271 Saint-Priest-en-Jarez, France
| | - E Botelho-Nevers
- Service des maladies infectieuses et tropicales, CHU de Saint-Étienne, 108, avenue Albert-Raimond, 42271 St-Priest, France
| | - J Cornillon
- Département d'hématologie clinique, institut de cancérologie Lucien-Neuwirth, 108 bis, avenue A.-Raimond, 42271 Saint-Priest-en-Jarez, France.
| |
Collapse
|
30
|
Gagneux-Brunon A, Boyer B, Ferry T, Lucht F, Cazorla C, Berthelot P, Botelho-Nevers E. Dépistage et décolonisation de Staphylococcus aureus en orthopédie : enquête de pratique auprès de centres français. Med Mal Infect 2018. [DOI: 10.1016/j.medmal.2018.04.232] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
31
|
Hoyon M, Detoc M, Boyer B, Berthelot P, Verhoeven P, Botelho-Nevers E. Connaissances et croyances sur les infections associées aux soins chez les patients allant bénéficier d’une pose de prothèse articulaire. Med Mal Infect 2018. [DOI: 10.1016/j.medmal.2018.04.212] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/14/2022]
|
32
|
Dufour S, Duval X, Faucanié M, Botelho-Nevers E, Chirouze C, Piroth L, Tattevin P, Picot M, Le moing V. Prise en charge diagnostique et thérapeutique des bactériémies à Staphylococcus aureus : consensus des infectiologues de 11 hôpitaux français. Med Mal Infect 2018. [DOI: 10.1016/j.medmal.2018.04.185] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/14/2022]
|
33
|
Gagneux-Brunon A, Lucht F, Launay O, Berthelot P, Botelho-Nevers E. Les vaccins dans la prévention des infections associées aux soins. Journal des Anti-infectieux 2017. [PMCID: PMC7148680 DOI: 10.1016/j.antinf.2017.05.001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Download PDF] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
Abstract
Les infections associées aux soins (IAS) constituent un véritable problème de santé publique. Escherichia coli, Staphylococcus aureus, Clostridium difficile sont les plus souvent à l’origine des IAS. L’antibiorésistance fréquente complique encore la prise en charge et des impasses thérapeutiques existent à présent. Les mesures d’hygiène hospitalière bien qu’essentielles sont insuffisantes pour diminuer drastiquement les IAS. Ainsi, des stratégies alternatives à l’antibiothérapie s’avèrent nécessaires pour prévenir et traiter les IAS. Parmi celles-ci, la vaccination et l’immunisation passive sont probablement les plus prometteuses. Nous avons fait une mise au point sur les vaccins disponibles et en développement clinique pour lutter contre les IAS, chez les patients à risque d’IAS et les soignants. L’intérêt de la vaccination grippale et rotavirus chez les patients pour prévenir ces IAS virales a été examiné. Le développement d’un vaccin anti-S. aureus, déjà émaillé de 2 échecs est complexe. Toutefois, ces échecs ont permis d’améliorer les connaissances sur l’immunité anti-S. aureus. La mise à disposition d’un vaccin préventif anti-C. difficile semble plus proche. Pour les autres bactéries gram négatif responsables d’IAS, le développement est moins avancé. La vaccination des patients à risques d’IAS pose également des problèmes de réponse vaccinale qu’il faudra résoudre pour utiliser cette stratégie. Ainsi, la vaccination des soignants, de par l’effet de groupe permet également de prévenir les IAS. Nous faisons ici le point sur l’intérêt de la vaccination des soignants contre la rougeole, la coqueluche, la grippe, la varicelle, l’hépatite B pour réduire les IAS avec des vaccins déjà disponibles.
Collapse
|
34
|
Pradat P, Pugliese P, Poizot-Martin I, Valantin MA, Cuzin L, Reynes J, Billaud E, Huleux T, Bani-Sadr F, Rey D, Frésard A, Jacomet C, Duvivier C, Cheret A, Hustache-Mathieu L, Hoen B, Cabié A, Cotte L, Chidiac C, Ferry T, Ader F, Biron F, Boibieux A, Miailhes P, Perpoint T, Schlienger I, Lippmann J, Braun E, Koffi J, Longuet C, Guéripel V, Augustin-Normand C, Brochier C, Degroodt S, Pugliese P, Ceppi C, Cua E, Cottalorda J, Courjon J, Dellamonica P, Demonchy E, De Monte A, Durant J, Etienne C, Ferrando S, Fuzibet J, Garraffo R, Joulie A, Risso K, Mondain V, Naqvi A, Oran N, Perbost I, Pillet S, Prouvost-Keller B, Wehrlen-Pugliese S, Rosenthal E, Sausse S, Rio V, Roger P, Brégigeon S, Faucher O, Obry-Roguet V, Orticoni M, Soavi M, Geneau de Lamarlière P, Laroche H, Ressiot E, Carta M, Ducassou M, Jacquet I, Gallie S, Galinier A, Ritleng A, Ivanova A, Blanco-Betancourt C, Lions C, Debreux C, Obry-Roguet V, Poizot-Martin I, Agher R, Katlama C, Valantin M, Duvivier C, Lortholary O, Lanternier F, Charlier C, Rouzaud C, Aguilar C, Henry B, Lebeaux D, Cessot G, Gergely A, Consigny P, Touam F, Louisin C, Alvarez M, Biezunski N, Cuzin L, Debard A, Delobel P, Delpierre C, Fourcade C, Marchou B, Martin-Blondel G, Porte M, Mularczyk M, Garipuy D, Saune K, Lepain I, Marcel M, Puntis E, Atoui N, Casanova M, Faucherre V, Jacquet J, Le Moing V, Makinson A, Merle De Boever C, Montoya-Ferrer A, Psomas C, Reynes J, Raffi F, Allavena C, Billaud E, Biron C, Bonnet B, Bouchez S, Boutoille D, Brunet C, Jovelin T, Hall N, Bernaud C, Morineau P, Reliquet V, Aubry O, Point P, Besnier M, Larmet L, Hüe H, Pineau S, André-Garnier E, Rodallec A, Choisy P, Vandame S, Huleux T, Ajana F, Alcaraz I, Baclet V, Huleux T, Melliez H, Viget N, Valette M, Aissi E, Allienne C, Meybeck A, Riff B, Bani-Sadr F, Rouger C, Berger J, N'Guyen Y, Lambert D, Kmiec I, Hentzien M, Lebrun D, Migault C, Rey D, Batard M, Bernard-Henry C, Cheneau C, de Mautort E, Fischer P, Partisani M, Priester M, Lucht F, Frésard A, Botelho-Nevers E, Gagneux-Brunon A, Cazorla C, Guglielminotti C, Daoud F, Lutz M, Jacomet C, Laurichesse H, Lesens O, Vidal M, Mrozek N, Corbin V, Aumeran C, Baud O, Casanova S, Coban D, Hustache-Mathieu L, Thiebaut-Drobacheff M, Foltzer A, Gendrin V, Bozon F, Chirouze C, Abel S, Cabié A, Césaire R, Santos GD, Fagour L, Najioullah F, Ouka M, Pierre-François S, Pircher M, Rozé B, Hoen B, Ouissa R, Lamaury I. Direct-acting antiviral treatment against hepatitis C virus infection in HIV-Infected patients - "En route for eradication"? J Infect 2017; 75:234-241. [PMID: 28579302 DOI: 10.1016/j.jinf.2017.05.008] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/10/2016] [Revised: 03/17/2017] [Accepted: 05/11/2017] [Indexed: 02/07/2023]
Abstract
OBJECTIVES Direct-Acting Antivirals (DAAs) opened a new era in HCV treatment. We report the impact of HCV treatment in French HIV-HCV coinfected patients. METHODS All HIV-HCV patients from the Dat'AIDS cohort followed between 2012 and 2015 were included. HCV status was defined yearly as naive, spontaneous cure, sustained virological response (SVR12), failure or reinfection. RESULTS Among 32,945 HIV-infected patients, 15.2% were positive for anti-HCV antibodies. From 2012 to 2015, HCV incidence rate increased from 0.35%PY to 0.69%PY in MSM, while median incidence was 0.08%PY in other patients. Median reinfection rate was 2.56%PY in MSM and 0.22%PY in other patients. HCV treatment initiation rate rose from 8.2% in 2012 to 29.6% (48.0% in pre-treated patients vs 22.6% in naïve patients). SVR12 rate increased from 68.7% to 95.2%. By the end of 2015, 62.7% of the patients were cured either spontaneously or following SVR. CONCLUSIONS HCV treatment dramatically increased in HIV-HCV patients in France from 2012 to 2015 resulting in HCV cure in nearly two-thirds of the patients in this cohort. Combined with a declining HCV prevalence, the prevalence of active HCV infection among HIV patients will drastically decrease in the forthcoming years.
Collapse
Affiliation(s)
- Pierre Pradat
- Center for Clinical Research, Department of Hepatology, Croix-Rousse Hospital, Hospices Civils de Lyon, Lyon, France.
| | - Pascal Pugliese
- Department of Infectious Diseases, Centre Hospitalier Universitaire de Nice, Hôpital l'Archet, Nice, France
| | - Isabelle Poizot-Martin
- Immuno-hematology Clinic, Assistance Publique - Hôpitaux de Marseille, Hôpital Sainte-Marguerite, Marseille, France; Aix-Marseille University, Inserm U912 (SESSTIM), Marseille, France
| | - Marc-Antoine Valantin
- Department of Infectious Diseases, Assistance Publique - Hôpitaux de Paris, Pitié-Salpêtrière Hospital, Paris, France; Sorbonne Universités, UPMC Université Paris 06, INSERM, Institut Pierre Louis d'épidémiologie et de Santé Publique (IPLESP UMRS 1136), Paris, France
| | - Lise Cuzin
- CHU Toulouse, COREVIH, Toulouse, France; Université de Toulouse III, Toulouse, France; INSERM, UMR, 1027, Toulouse, France
| | - Jacques Reynes
- Department of Infectious Diseases, UMI 233 INSERM U1175, CHU de Montpellier, Montpellier, France
| | - Eric Billaud
- Department of Infectious Diseases, Hotel Dieu Hospital, Nantes, France
| | - Thomas Huleux
- Department of Infectious Diseases and Travel Diseases, Centre Hospitalier Gustave-Dron, Tourcoing, France
| | - Firouze Bani-Sadr
- Department of Internal Medicine, Infectious Diseases and Clinical Immunology, Hôpital Robert Debré, CHU, Reims, France; Université de Reims Champagne-Ardenne, Faculté de médecine, EA-4684/SFR CAP-SANTE, Reims, France
| | - David Rey
- HIV Infection Care Centre, Hôpitaux Universitaires, Strasbourg, France
| | - Anne Frésard
- Department of Infectious Diseases, CHU, Saint-Etienne, France
| | - Christine Jacomet
- Department of Infectious Diseases, CHU Clermont-Ferrand, Clermont-Ferrand, France
| | - Claudine Duvivier
- Department of Infectious Diseases, Centre d'Infectiologie Necker-Pasteur, IHU Imagine, Assistance Publique - Hôpitaux de Paris, Hôpital Necker-Enfants Malades, Paris, France; Université Paris Descartes, Sorbonne Paris Cité, EA7327, Paris, France
| | - Antoine Cheret
- Department of Internal Medicine, CHU, Bicètre, France; Université Paris Descartes, Sorbonne Paris Cité, EA7327, Paris, France
| | | | - Bruno Hoen
- Faculté de Médecine Hyacinthe Bastaraud, Université des Antilles, and Service de Maladies Infectieuses et Tropicales, Dermatologie et Médecine Interne, and Inserm CIC 1424, Centre Hospitalier Universitaire de Pointe-à-Pitre, Pointe-à-Pitre, France
| | - André Cabié
- Department of Infectious Diseases, CHU de Martinique, Fort-de-France, France; Université des Antilles EA4537 and INSERM CIC1424, Fort-de-France, France
| | - Laurent Cotte
- Department of Infectious Diseases, Croix-Rousse Hospital, Hospices Civils de Lyon, Lyon, France; INSERM U1052, Lyon, France.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
35
|
Aba Y, Kone D, Diallo Z, Kra O, Botelho-Nevers E, Lucht F, Bissagnene E. Méningites bactériennes et infection par le VIH : analyse d’une série hospitalière dans un CHU de Côte d’Ivoire. Med Mal Infect 2017. [DOI: 10.1016/j.medmal.2017.03.229] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
36
|
Aba Y, Kra O, Kadiane J, Botelho-Nevers E, Lucht F, Bissagnene E. Caractéristiques et prise en charge thérapeutique des cas de Trypanosomiase humaine Africaine dans un centre de traitement spécialisé en Côte d’Ivoire. Med Mal Infect 2017. [DOI: 10.1016/j.medmal.2017.03.241] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
37
|
Petrosyan E, Ferry T, Forestier E, Botelho-Nevers E, Maillet M, Piet E, Pereira B, Lustig S, Descamps S, Lesens O. Pronostic des infections de prothèses orthopédiques à S. aureus traitées par lavage : étude rétrospective multicentrique. Med Mal Infect 2017. [DOI: 10.1016/j.medmal.2017.03.034] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
38
|
Gagnaire J, Gagneux-Brunon A, Pouvaret A, Grattard F, Carricajo A, Favier H, Mattei A, Pozzetto B, Nuti C, Lucht F, Berthelot P, Botelho-Nevers E. Carbapenemase-producing Acinetobacter baumannii: An outbreak report with special highlights on economic burden. Med Mal Infect 2017; 47:279-285. [PMID: 28343727 DOI: 10.1016/j.medmal.2017.02.006] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/15/2016] [Revised: 05/31/2016] [Accepted: 02/20/2017] [Indexed: 11/17/2022]
Abstract
OBJECTIVE We aimed to describe the management of a carbapenemase-producing Acinetobacter baumannii (CP-AB) outbreak using the Outbreak Reports and Intervention Studies of Nosocomial Infection (ORION) statement. We also aimed to evaluate the cost of the outbreak and simulate costs if a dedicated unit to manage such outbreak had been set-up. METHODS We performed a prospective epidemiological study. Multiple interventions were implemented including cohorting measures and limitation of admissions. Cost estimation was performed using administrative local data. RESULTS Five patients were colonized with CP-AB and hospitalized in the neurosurgery ward. The index case was a patient who had been previously hospitalized in Portugal. Four secondary colonized patients were further observed within the unit. The strains of A. baumannii were shown to belong to the same clone and all of them produced an OXA-23 carbapenemase. The closure of the ward associated with the discharge of the five patients in a cohorting area of the Infectious Diseases Unit with dedicated staff put a stop to the outbreak. The estimated cost of this 17-week outbreak was $474,474. If patients had been managed in a dedicated unit - including specific area for cohorting of patients and dedicated staff - at the beginning of the outbreak, the estimated cost would have been $189,046. CONCLUSION Controlling hospital outbreaks involving multidrug-resistant bacteria requires a rapid cohorting of patients. Using simulation, we highlighted cost gain when using a dedicated cohorting unit strategy for such an outbreak.
Collapse
Affiliation(s)
- J Gagnaire
- Infection control unit, infectious diseases department, university hospital of Saint-Étienne, 42055 Saint-Étienne cedex 2, France
| | - A Gagneux-Brunon
- Infection control unit, infectious diseases department, university hospital of Saint-Étienne, 42055 Saint-Étienne cedex 2, France
| | - A Pouvaret
- Infection control unit, infectious diseases department, university hospital of Saint-Étienne, 42055 Saint-Étienne cedex 2, France
| | - F Grattard
- Laboratory of infectious agents and hygiene, university hospital of Saint-Étienne, 42055 Saint-Étienne cedex 2, France
| | - A Carricajo
- Laboratory of infectious agents and hygiene, university hospital of Saint-Étienne, 42055 Saint-Étienne cedex 2, France
| | - H Favier
- Infection control unit, infectious diseases department, university hospital of Saint-Étienne, 42055 Saint-Étienne cedex 2, France
| | - A Mattei
- Infection control unit, infectious diseases department, university hospital of Saint-Étienne, 42055 Saint-Étienne cedex 2, France
| | - B Pozzetto
- Laboratory of infectious agents and hygiene, university hospital of Saint-Étienne, 42055 Saint-Étienne cedex 2, France
| | - C Nuti
- Neurosurgery unit, university hospital of Saint-Étienne, 42055 Saint-Étienne cedex 2, France
| | - F Lucht
- Infection control unit, infectious diseases department, university hospital of Saint-Étienne, 42055 Saint-Étienne cedex 2, France
| | - P Berthelot
- Infection control unit, infectious diseases department, university hospital of Saint-Étienne, 42055 Saint-Étienne cedex 2, France; Laboratory of infectious agents and hygiene, university hospital of Saint-Étienne, 42055 Saint-Étienne cedex 2, France.
| | - E Botelho-Nevers
- Infection control unit, infectious diseases department, university hospital of Saint-Étienne, 42055 Saint-Étienne cedex 2, France
| |
Collapse
|
39
|
Tissot-Dupont H, Casalta JP, Gouriet F, Hubert S, Salaun E, Habib G, Fernandez-Gerlinger MP, Mainardi JL, Tattevin P, Revest M, Lucht F, Botelho-Nevers E, Gagneux-Brunon A, Snygg-Martin U, Chan KL, Bishara J, Vilacosta I, Olmos C, San Román JA, López J, Tornos P, Fernández-Hidalgo N, Durante-Mangoni E, Utili R, Paul M, Baddour LM, DeSimone DC, Sohail MR, Steckelberg JM, Wilson WR, Raoult D. International experts' practice in the antibiotic therapy of infective endocarditis is not following the guidelines. Clin Microbiol Infect 2017; 23:736-739. [PMID: 28323194 DOI: 10.1016/j.cmi.2017.03.007] [Citation(s) in RCA: 21] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/29/2016] [Revised: 03/06/2017] [Accepted: 03/10/2017] [Indexed: 12/12/2022]
Abstract
OBJECTIVE The management of infective endocarditis (IE) may differ from international guidelines, even in reference centres. This is probably because most recommendations are not based on hard evidence, so the consensus obtained for the guidelines does not represent actual practices. For this reason, we aimed to evaluate this question in the particular field of antibiotic therapy. METHODS Thirteen international centres specialized in the management of IE were selected, according to their reputation, clinical results, original research publications and quotations. They were asked to detail their actual practice in terms of IE antibiotic treatment in various bacteriological and clinical situations. They were also asked to declare their IE-related in-hospital mortality for the year 2015. RESULTS The global compliance with guidelines concerning antibiotic therapy was 58%, revealing the differences between theoretical 'consensus', local recommendations and actual practice. Some conflicts of interest were also probably expressed. The adherence to guidelines was 100% when the protocol was simple, and decreased with the seriousness of the situation (Staphylococus spp. 54%-62%) or in blood-culture-negative endocarditis (0%-15%) that requires adaptation to clinical and epidemiological data. CONCLUSION Worldwide experts in IE management, although the majority of them were involved and co-signed the guidelines, do not follow international consensus guidelines on the particular point of the use of antibiotics.
Collapse
Affiliation(s)
- H Tissot-Dupont
- URMITE, Aix Marseille Université, UMR 7278, IRD 198, INSERM 1095, IHU-Méditerranée Infection, Marseille, France
| | - J P Casalta
- URMITE, Aix Marseille Université, UMR 7278, IRD 198, INSERM 1095, IHU-Méditerranée Infection, Marseille, France
| | - F Gouriet
- URMITE, Aix Marseille Université, UMR 7278, IRD 198, INSERM 1095, IHU-Méditerranée Infection, Marseille, France
| | - S Hubert
- Département de Cardiologie, Centre Hospitalier Universitaire, Hôpital de La Timone, AP-HM, Aix-Marseille Université, Marseille, France
| | - E Salaun
- Département de Cardiologie, Centre Hospitalier Universitaire, Hôpital de La Timone, AP-HM, Aix-Marseille Université, Marseille, France
| | - G Habib
- Département de Cardiologie, Centre Hospitalier Universitaire, Hôpital de La Timone, AP-HM, Aix-Marseille Université, Marseille, France
| | - M P Fernandez-Gerlinger
- Unité Mobile de Microbiologie Clinique, Service de Microbiologie, Hôpital européen Georges-Pompidou, Université Paris Descartes, Paris, France
| | - J L Mainardi
- Unité Mobile de Microbiologie Clinique, Service de Microbiologie, Hôpital européen Georges-Pompidou, Université Paris Descartes, Paris, France
| | - P Tattevin
- Service des Maladies Infectieuses et de Réanimation Médicale, Hôpital Pontchaillou, Université Rennes-I, Rennes, France
| | - M Revest
- Service des Maladies Infectieuses et de Réanimation Médicale, Hôpital Pontchaillou, Université Rennes-I, Rennes, France
| | - F Lucht
- Infectious Diseases Department, University Hospital of Saint-Etienne, France
| | - E Botelho-Nevers
- Infectious Diseases Department, University Hospital of Saint-Etienne, France
| | - A Gagneux-Brunon
- Infectious Diseases Department, University Hospital of Saint-Etienne, France
| | - U Snygg-Martin
- Department of Infectious Diseases, Sahlgrenska University Hospital, Gothenburg, Sweden
| | - K L Chan
- University of Ottawa Heart Institute, Ottawa, Ontario, Canada
| | - J Bishara
- Infectious Disease Unit Rabin Medical Centre, Beilinson Hospital Sackler Faculty of Medicine, Tel-Aviv University, Jabotinsky 39, Petah-Tiqva, Israel
| | - I Vilacosta
- Servicio de Cardiología, Instituto de Investigación Sanitaria Hospital Clínico San Carlos, Madrid, Spain
| | - C Olmos
- Servicio de Cardiología, Instituto de Investigación Sanitaria Hospital Clínico San Carlos, Madrid, Spain
| | - J A San Román
- Servicio de Cardiología, Instituto de Ciencias del Corazón (ICICOR), Hospital Clínico Universitario, Valladolid, Spain
| | - J López
- Servicio de Cardiología, Instituto de Ciencias del Corazón (ICICOR), Hospital Clínico Universitario, Valladolid, Spain
| | - P Tornos
- Servei de Malalties Infeccioses, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Spain
| | - N Fernández-Hidalgo
- Servei de Malalties Infeccioses, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Spain
| | - E Durante-Mangoni
- Internal Medicine, University of Naples SUN, Monaldi Hospital, Naples, Italy
| | - R Utili
- Internal Medicine, University of Naples SUN, Monaldi Hospital, Naples, Italy
| | - M Paul
- Ramban Health Care Campus, Haifa, Israel
| | - L M Baddour
- Division of Infectious Diseases, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA
| | - D C DeSimone
- Division of Infectious Diseases, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA
| | - M R Sohail
- Division of Infectious Diseases, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA
| | - J M Steckelberg
- Division of Infectious Diseases, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA
| | - W R Wilson
- Division of Infectious Diseases, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA
| | - D Raoult
- URMITE, Aix Marseille Université, UMR 7278, IRD 198, INSERM 1095, IHU-Méditerranée Infection, Marseille, France.
| |
Collapse
|
40
|
Detoc M, Gagneux-Brunon A, Lucht F, Botelho-Nevers E. Barriers and motivations to volunteers' participation in preventive vaccine trials: a systematic review. Expert Rev Vaccines 2017; 16:467-477. [PMID: 28277098 DOI: 10.1080/14760584.2017.1297706] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/23/2023]
Abstract
INTRODUCTION The recruitment of volunteers in preventive vaccine trials (PVT) is a challenge, since vaccine hesitancy and debates on vaccines are combined to usual difficulties of enrollment in clinical trials. Areas covered: Current knowledge of the reasons leading to the volunteers' participation or non-participation in PVT mainly focuses on data from preventive HIV vaccine trials. A systematic PubMed search was conducted using PRISMA guidelines to identify articles or reviews that reported barriers and motivations to participation in PVT regardless of the targeted disease or population. Expert commentary: In view of the barriers and motivations reviewed here, improvements in recruitment could be made through a better explanation of the prevented disease, of the expected individual and collective benefit and of all ethical protective principles associated to the trials. Use of decision aids as well as patient and public involvement may improve given information and may enhance comprehension of participants and their participation in PVT. Further prospective and interventional studies are needed to analyze if these leads may improve acceptation level in PVT.
Collapse
Affiliation(s)
- M Detoc
- a Clinical Trial Center , INSERM CIC 1408, University Hospital of Saint-Etienne , Saint-Etienne , France.,b Groupe Immunité Muqueuse et Agents Pathogènes (GIMAP), EA3064 , Medical School of Saint-Etienne, University of Lyon , Saint-Etienne , France
| | - A Gagneux-Brunon
- a Clinical Trial Center , INSERM CIC 1408, University Hospital of Saint-Etienne , Saint-Etienne , France.,b Groupe Immunité Muqueuse et Agents Pathogènes (GIMAP), EA3064 , Medical School of Saint-Etienne, University of Lyon , Saint-Etienne , France
| | - F Lucht
- a Clinical Trial Center , INSERM CIC 1408, University Hospital of Saint-Etienne , Saint-Etienne , France.,b Groupe Immunité Muqueuse et Agents Pathogènes (GIMAP), EA3064 , Medical School of Saint-Etienne, University of Lyon , Saint-Etienne , France
| | - E Botelho-Nevers
- a Clinical Trial Center , INSERM CIC 1408, University Hospital of Saint-Etienne , Saint-Etienne , France.,b Groupe Immunité Muqueuse et Agents Pathogènes (GIMAP), EA3064 , Medical School of Saint-Etienne, University of Lyon , Saint-Etienne , France
| |
Collapse
|
41
|
Botelho-Nevers E, Gagnaire J, Verhoeven PO, Cazorla C, Grattard F, Pozzetto B, Berthelot P, Lucht F. Decolonization of Staphylococcus aureus carriage. Med Mal Infect 2016; 47:305-310. [PMID: 27856080 DOI: 10.1016/j.medmal.2016.10.005] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/08/2015] [Revised: 04/25/2016] [Accepted: 10/11/2016] [Indexed: 10/20/2022]
Abstract
Staphylococcus aureus nasal colonization is a well-known independent risk factor for infection caused by this bacterium. Screening and decolonization of carriers have been proven effective in reducing S. aureus infections in some populations. However, a gap remains between what has been proven effective and what is currently done. We aimed to summarize recommendations and current knowledge of S. aureus decolonization to answer the following questions: Why? For whom? How? When? And what are the perspectives?
Collapse
Affiliation(s)
- E Botelho-Nevers
- Infectious diseases department, university hospital of Saint-Étienne, avenue Albert-Raimond, 42055 Saint-Étienne cedex 02, France; Groupe immunité des muqueuses et agents pathogènes (GIMAP EA 3064), university of Lyon, 42023 Saint-Étienne, France.
| | - J Gagnaire
- Infectious diseases department, university hospital of Saint-Étienne, avenue Albert-Raimond, 42055 Saint-Étienne cedex 02, France; Groupe immunité des muqueuses et agents pathogènes (GIMAP EA 3064), university of Lyon, 42023 Saint-Étienne, France; Laboratory of infectious agents and hygiene, university hospital of Saint-Étienne, 42055 Saint-Étienne cedex 02, France
| | - P O Verhoeven
- Groupe immunité des muqueuses et agents pathogènes (GIMAP EA 3064), university of Lyon, 42023 Saint-Étienne, France; Laboratory of infectious agents and hygiene, university hospital of Saint-Étienne, 42055 Saint-Étienne cedex 02, France
| | - C Cazorla
- Infectious diseases department, university hospital of Saint-Étienne, avenue Albert-Raimond, 42055 Saint-Étienne cedex 02, France; Groupe immunité des muqueuses et agents pathogènes (GIMAP EA 3064), university of Lyon, 42023 Saint-Étienne, France
| | - F Grattard
- Groupe immunité des muqueuses et agents pathogènes (GIMAP EA 3064), university of Lyon, 42023 Saint-Étienne, France; Laboratory of infectious agents and hygiene, university hospital of Saint-Étienne, 42055 Saint-Étienne cedex 02, France
| | - B Pozzetto
- Groupe immunité des muqueuses et agents pathogènes (GIMAP EA 3064), university of Lyon, 42023 Saint-Étienne, France; Laboratory of infectious agents and hygiene, university hospital of Saint-Étienne, 42055 Saint-Étienne cedex 02, France
| | - P Berthelot
- Infectious diseases department, university hospital of Saint-Étienne, avenue Albert-Raimond, 42055 Saint-Étienne cedex 02, France; Groupe immunité des muqueuses et agents pathogènes (GIMAP EA 3064), university of Lyon, 42023 Saint-Étienne, France; Laboratory of infectious agents and hygiene, university hospital of Saint-Étienne, 42055 Saint-Étienne cedex 02, France
| | - F Lucht
- Infectious diseases department, university hospital of Saint-Étienne, avenue Albert-Raimond, 42055 Saint-Étienne cedex 02, France; Groupe immunité des muqueuses et agents pathogènes (GIMAP EA 3064), university of Lyon, 42023 Saint-Étienne, France
| |
Collapse
|
42
|
Pillet S, Berthelot P, Gagneux-Brunon A, Mory O, Gay C, Viallon A, Lucht F, Pozzetto B, Botelho-Nevers E. Corrigendum to "Contamination of healthcare workers' mobile phones by epidemic viruses" [Clin Microbiol Infect (2016) 456.e1-456.e6]. Clin Microbiol Infect 2016; 22:e21. [PMID: 27457787 PMCID: PMC8445313 DOI: 10.1016/j.cmi.2016.07.024] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Affiliation(s)
- S Pillet
- GIMAP EA 3064 (Groupe Immunité des Muqueuses et Agents Pathogènes), University of Lyon, Saint-Etienne, France; Laboratory of Infectious Agents and Hygiene, University Hospital of Saint-Étienne, Saint-Étienne, France
| | - P Berthelot
- GIMAP EA 3064 (Groupe Immunité des Muqueuses et Agents Pathogènes), University of Lyon, Saint-Etienne, France; Laboratory of Infectious Agents and Hygiene, University Hospital of Saint-Étienne, Saint-Étienne, France; Infectious Diseases Department, University Hospital of Saint-Étienne, Saint-Étienne, France
| | - A Gagneux-Brunon
- GIMAP EA 3064 (Groupe Immunité des Muqueuses et Agents Pathogènes), University of Lyon, Saint-Etienne, France; Infectious Diseases Department, University Hospital of Saint-Étienne, Saint-Étienne, France
| | - O Mory
- Paediatric Emergency Department, University Hospital of Saint-Étienne, Saint-Étienne, France
| | - C Gay
- Paediatric Department, University Hospital of Saint-Étienne, Saint-Étienne, France
| | - A Viallon
- Adult Emergency Department, University Hospital of Saint-Étienne, Saint-Étienne, France
| | - F Lucht
- GIMAP EA 3064 (Groupe Immunité des Muqueuses et Agents Pathogènes), University of Lyon, Saint-Etienne, France; Infectious Diseases Department, University Hospital of Saint-Étienne, Saint-Étienne, France
| | - B Pozzetto
- GIMAP EA 3064 (Groupe Immunité des Muqueuses et Agents Pathogènes), University of Lyon, Saint-Etienne, France; Laboratory of Infectious Agents and Hygiene, University Hospital of Saint-Étienne, Saint-Étienne, France
| | - E Botelho-Nevers
- GIMAP EA 3064 (Groupe Immunité des Muqueuses et Agents Pathogènes), University of Lyon, Saint-Etienne, France; Infectious Diseases Department, University Hospital of Saint-Étienne, Saint-Étienne, France.
| |
Collapse
|
43
|
Pillard M, Frésard A, Gagneux-Brunon A, Lucht F, Charles R, Botelho-Nevers E. VIH-03 - Dépistage VIH en médecine générale : quelles sont les occasions manquées? Med Mal Infect 2016. [DOI: 10.1016/s0399-077x(16)30548-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
44
|
Moriceau G, Gagneux-Brunon A, Gagnaire J, Mariat C, Lucht F, Berthelot P, Botelho-Nevers E. Preventing healthcare-associated infections: Residents and attending physicians need better training in advanced isolation precautions. Med Mal Infect 2016; 46:14-9. [DOI: 10.1016/j.medmal.2015.11.001] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/23/2015] [Revised: 08/20/2015] [Accepted: 11/02/2015] [Indexed: 12/09/2022]
|
45
|
Pillet S, Berthelot P, Gagneux-Brunon A, Mory O, Gay C, Viallon A, Lucht F, Pozzetto B, Botelho-Nevers E. Contamination of healthcare workers' mobile phones by epidemic viruses. Clin Microbiol Infect 2015; 22:456.e1-6. [PMID: 26713553 PMCID: PMC7129817 DOI: 10.1016/j.cmi.2015.12.008] [Citation(s) in RCA: 27] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/06/2015] [Revised: 12/04/2015] [Accepted: 12/10/2015] [Indexed: 11/26/2022]
Abstract
Mobile phones (MPs) are potential reservoirs of nosocomial bacteria, but few data are available concerning viruses. We aimed to evaluate the presence of virus RNA from epidemic viruses including metapneumovirus, respiratory syncytial virus, influenza viruses, rotavirus (RV) and norovirus on the MPs used by healthcare workers (HCWs) and to relate it to hygiene measures. An anonymous behavioural questionnaire about MP use at hospital was administered to the HCWs of four adult and paediatric departments of a university hospital. After sampling personal (PMP) and/or professional MPs (digital enhanced cordless telephone, DECT), virus RNAs were extracted and amplified by one-step real-time reverse transcription–quantitative PCR. The molecular results were analysed in a masked manner in relation to the behavioural survey. Questionnaires from 114 HCWs (35 senior physicians, 30 residents, 32 nurses, 27 nurses' assistants) working either in adult (n = 58) or paediatric (n = 56) departments were analysed. Medical personnel used their PMP more frequently than paramedical HCWs (33/65 vs. 10/59, p <0.001). MPs were used during care more frequently in adult wards than in paediatric ones (46/58 vs. 27/56, p <0.001). Virus RNA was detected on 42/109 (38.5%) collected MPs, with RV found on 39, respiratory syncytial virus on three and metapneumovirus on one. The presence of virus RNA was significantly associated with MPs from the paediatric HCWs (p <0.001). MPs routinely used in hospital, even during care, can host virus RNA, especially RV. Promotion of frequent hand hygiene before and after MP use, along with frequent cleaning of MPs, should be encouraged.
Collapse
Affiliation(s)
- S Pillet
- GIMAP EA 3064 (Groupe Immunité des Muqueuses et Agents Pathogènes), University of Lyon, Saint-Etienne, France; Laboratory of Infectious Agents and Hygiene, University Hospital of Saint-Étienne, Saint-Étienne, France
| | - P Berthelot
- GIMAP EA 3064 (Groupe Immunité des Muqueuses et Agents Pathogènes), University of Lyon, Saint-Etienne, France; Laboratory of Infectious Agents and Hygiene, University Hospital of Saint-Étienne, Saint-Étienne, France; Infectious Diseases Department, University Hospital of Saint-Étienne, Saint-Étienne, France
| | - A Gagneux-Brunon
- GIMAP EA 3064 (Groupe Immunité des Muqueuses et Agents Pathogènes), University of Lyon, Saint-Etienne, France; Infectious Diseases Department, University Hospital of Saint-Étienne, Saint-Étienne, France
| | - O Mory
- Paediatric Emergency Department, University Hospital of Saint-Étienne, Saint-Étienne, France
| | - C Gay
- Paediatric Department, University Hospital of Saint-Étienne, Saint-Étienne, France
| | - A Viallon
- Adult Emergency Department, University Hospital of Saint-Étienne, Saint-Étienne, France
| | - F Lucht
- GIMAP EA 3064 (Groupe Immunité des Muqueuses et Agents Pathogènes), University of Lyon, Saint-Etienne, France; Infectious Diseases Department, University Hospital of Saint-Étienne, Saint-Étienne, France
| | - B Pozzetto
- GIMAP EA 3064 (Groupe Immunité des Muqueuses et Agents Pathogènes), University of Lyon, Saint-Etienne, France; Laboratory of Infectious Agents and Hygiene, University Hospital of Saint-Étienne, Saint-Étienne, France
| | - E Botelho-Nevers
- GIMAP EA 3064 (Groupe Immunité des Muqueuses et Agents Pathogènes), University of Lyon, Saint-Etienne, France; Infectious Diseases Department, University Hospital of Saint-Étienne, Saint-Étienne, France.
| |
Collapse
|
46
|
Gagneux-Brunon A, Pillet S, Laurent B, Mariat C, Michalet M, Lucht F, Botelho-Nevers E. A case of BK virus nephropathy in a stem cell transplant recipient: a rare or under-recognized cause for Acute Kidney injury. Med Mal Infect 2015; 45:331-4. [PMID: 26144286 DOI: 10.1016/j.medmal.2015.06.001] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/20/2015] [Revised: 05/18/2015] [Accepted: 06/03/2015] [Indexed: 11/29/2022]
Affiliation(s)
- A Gagneux-Brunon
- Service de Maladies Infectieuses et Tropicales, CHU de Saint-Étienne, 42055 Saint-Étienne cedex 2, France; Groupe Immunité des Muqueuses et Agents Pathogènes, EA 3064, Université Jean-Monnet, Université de Lyon, CHU de Saint-Étienne, 42000 Saint-Étienne, France.
| | - S Pillet
- Groupe Immunité des Muqueuses et Agents Pathogènes, EA 3064, Université Jean-Monnet, Université de Lyon, CHU de Saint-Étienne, 42000 Saint-Étienne, France; Laboratoire de Bactériologie et Virologie, CHU de Saint-Étienne, 42055 Saint-Étienne, France
| | - B Laurent
- Laboratoire de Cytologie et Histologie rénale, CHU de Saint-Étienne, 42055 Saint-Étienne, France
| | - C Mariat
- Groupe Immunité des Muqueuses et Agents Pathogènes, EA 3064, Université Jean-Monnet, Université de Lyon, CHU de Saint-Étienne, 42000 Saint-Étienne, France; Service de Néphrologie, Dialyse, Transplantation et Hypertension, CHU de Saint-Étienne, 42055 Saint-Étienne, France
| | - M Michalet
- Service d'Hématologie, Hôpitaux Sud, Hospices Civils de Lyon, 69495 Pierre-Bénite, France
| | - F Lucht
- Service de Maladies Infectieuses et Tropicales, CHU de Saint-Étienne, 42055 Saint-Étienne cedex 2, France; Groupe Immunité des Muqueuses et Agents Pathogènes, EA 3064, Université Jean-Monnet, Université de Lyon, CHU de Saint-Étienne, 42000 Saint-Étienne, France
| | - E Botelho-Nevers
- Service de Maladies Infectieuses et Tropicales, CHU de Saint-Étienne, 42055 Saint-Étienne cedex 2, France; Groupe Immunité des Muqueuses et Agents Pathogènes, EA 3064, Université Jean-Monnet, Université de Lyon, CHU de Saint-Étienne, 42000 Saint-Étienne, France
| |
Collapse
|
47
|
Forest F, Cinotti E, Habougit C, Ginguéné C, Perrot JL, Labeille B, Flori P, Botelho-Nevers E, Péoćh M. Rapid characterization of human brain aspergillosis by confocal microscopy on a thick squash preparation. Cytopathology 2015; 27:221-2. [PMID: 26126596 DOI: 10.1111/cyt.12258] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Affiliation(s)
- F Forest
- Department of Pathology, University Hospital of Saint Etienne, North Hospital, Saint Etienne CEDEX 2, France
| | - E Cinotti
- Department of Dermatology, University Hospital of Saint Etienne, North Hospital, Saint Etienne CEDEX 2, France
| | - C Habougit
- Department of Pathology, University Hospital of Saint Etienne, North Hospital, Saint Etienne CEDEX 2, France
| | - C Ginguéné
- Department of Neurosurgery, University Hospital of Saint Etienne, North Hospital, Saint Etienne CEDEX 2, France
| | - J-L Perrot
- Department of Dermatology, University Hospital of Saint Etienne, North Hospital, Saint Etienne CEDEX 2, France
| | - B Labeille
- Department of Dermatology, University Hospital of Saint Etienne, North Hospital, Saint Etienne CEDEX 2, France
| | - P Flori
- Department of Mycology, University Hospital of Saint Etienne, North Hospital, Saint Etienne CEDEX 2, France
| | - E Botelho-Nevers
- Department of Infectious Diseases, University Hospital of Saint Etienne, North Hospital, Saint Etienne CEDEX 2, France
| | - M Péoćh
- Department of Pathology, University Hospital of Saint Etienne, North Hospital, Saint Etienne CEDEX 2, France
| |
Collapse
|
48
|
Verhoeven PO, Gautret P, Haddar CH, Benkouiten S, Gagnaire J, Belhouchat K, Grattard F, Charrel R, Pozzetto B, Drali T, Lucht F, Brouqui P, Memish ZA, Berthelot P, Botelho-Nevers E. Molecular dynamics of Staphylococcus aureus nasal carriage in Hajj pilgrims. Clin Microbiol Infect 2015; 21:650.e5-8. [PMID: 25882367 DOI: 10.1016/j.cmi.2015.03.020] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/18/2015] [Revised: 03/22/2015] [Accepted: 03/26/2015] [Indexed: 12/21/2022]
Abstract
During the 2012 Hajj season, the risk of acquisition of Staphylococcus aureus nasal carriage in a cohort of French pilgrims was 22.8%, and was statistically associated with the acquisition of viral respiratory pathogens (p 0.03). The carriage of S. aureus belonging to the emerging clonal complex 398 significantly increased following the pilgrimage (p < 0.05).
Collapse
Affiliation(s)
- P O Verhoeven
- GIMAP EA 3064 (Groupe Immunité des Muqueuses et Agents Pathogènes), University of Lyon, Saint-Etienne, France; Laboratory of Infectious Agents and Hygiene, University Hospital of Saint-Etienne, Saint-Etienne, France
| | - P Gautret
- Aix Marseille Université, URMITE, UM63, CNRS 7278, IRD 198, Inserm 1095 and Institut Hospitalo-Universitaire Méditerranée Infection, Marseille, France
| | - C H Haddar
- Laboratory of Infectious Agents and Hygiene, University Hospital of Saint-Etienne, Saint-Etienne, France
| | - S Benkouiten
- Aix Marseille Université, URMITE, UM63, CNRS 7278, IRD 198, Inserm 1095 and Institut Hospitalo-Universitaire Méditerranée Infection, Marseille, France
| | - J Gagnaire
- GIMAP EA 3064 (Groupe Immunité des Muqueuses et Agents Pathogènes), University of Lyon, Saint-Etienne, France
| | - K Belhouchat
- Aix Marseille Université, URMITE, UM63, CNRS 7278, IRD 198, Inserm 1095 and Institut Hospitalo-Universitaire Méditerranée Infection, Marseille, France
| | - F Grattard
- GIMAP EA 3064 (Groupe Immunité des Muqueuses et Agents Pathogènes), University of Lyon, Saint-Etienne, France; Laboratory of Infectious Agents and Hygiene, University Hospital of Saint-Etienne, Saint-Etienne, France
| | - R Charrel
- Aix Marseille Université, URMITE, UM63, CNRS 7278, IRD 198, Inserm 1095 and Institut Hospitalo-Universitaire Méditerranée Infection, Marseille, France
| | - B Pozzetto
- GIMAP EA 3064 (Groupe Immunité des Muqueuses et Agents Pathogènes), University of Lyon, Saint-Etienne, France; Laboratory of Infectious Agents and Hygiene, University Hospital of Saint-Etienne, Saint-Etienne, France
| | - T Drali
- Aix Marseille Université, URMITE, UM63, CNRS 7278, IRD 198, Inserm 1095 and Institut Hospitalo-Universitaire Méditerranée Infection, Marseille, France
| | - F Lucht
- GIMAP EA 3064 (Groupe Immunité des Muqueuses et Agents Pathogènes), University of Lyon, Saint-Etienne, France; Infectious Diseases Department, University Hospital of Saint-Etienne, Saint-Etienne, France
| | - P Brouqui
- Aix Marseille Université, URMITE, UM63, CNRS 7278, IRD 198, Inserm 1095 and Institut Hospitalo-Universitaire Méditerranée Infection, Marseille, France
| | - Z A Memish
- Public Health Directorate, Saudi Ministry of Health, World Health Organization Collaborating Centre for Mass Gathering Medicine and College of Medicine, Alfaisal University, Riyadh, Kingdom of Saudi Arabia
| | - P Berthelot
- GIMAP EA 3064 (Groupe Immunité des Muqueuses et Agents Pathogènes), University of Lyon, Saint-Etienne, France; Laboratory of Infectious Agents and Hygiene, University Hospital of Saint-Etienne, Saint-Etienne, France; Infectious Diseases Department, University Hospital of Saint-Etienne, Saint-Etienne, France
| | - E Botelho-Nevers
- GIMAP EA 3064 (Groupe Immunité des Muqueuses et Agents Pathogènes), University of Lyon, Saint-Etienne, France; Infectious Diseases Department, University Hospital of Saint-Etienne, Saint-Etienne, France.
| |
Collapse
|
49
|
Pulcini C, Botelho-Nevers E, Dyar OJ, Harbarth S. The impact of infectious disease specialists on antibiotic prescribing in hospitals. Clin Microbiol Infect 2014; 20:963-72. [PMID: 25039787 DOI: 10.1111/1469-0691.12751] [Citation(s) in RCA: 76] [Impact Index Per Article: 7.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
Given the current bacterial resistance crisis, antimicrobial stewardship programmes are of the utmost importance. We present a narrative review of the impact of infectious disease specialists (IDSs) on the quality and quantity of antibiotic use in acute-care hospitals, and discuss the main factors that could limit the efficacy of IDS recommendations. A total of 31 studies were included in this review, with a wide range of infections, hospital settings, and types of antibiotic prescription. Seven of 31 studies were randomized controlled trials, before/after controlled studies, or before/after uncontrolled studies with interrupted time-series analysis. In almost all studies, IDS intervention was associated with a significant improvement in the appropriateness of antibiotic prescribing as compared with prescriptions without any IDS input, and with decreased antibiotic consumption. Variability in the antibiotic prescribing practices of IDSs, informal (curbside) consultations and the involvement of junior IDSs are among the factors that could have an impact on the efficacy of IDS recommendations and on compliance rates, and deserve further investigation. We also discuss possible drawbacks of IDSs in acute-care hospitals that are rarely reported in the published literature. Overall, IDSs are valuable to antimicrobial stewardship programmes in hospitals, but their impact depends on many human and organizational factors.
Collapse
Affiliation(s)
- C Pulcini
- Service de Maladies Infectieuses, CHU de Nancy, Nancy, France; Université de Lorraine, EA 4360 APEMAC, Nancy, France
| | | | | | | |
Collapse
|
50
|
Botelho-Nevers E, Laurencin S, Delmont J, Parola P. Imported malaria in pregnancy: a retrospective study of 18 cases in Marseilles, France. Annals of Tropical Medicine & Parasitology 2013; 99:715-8. [PMID: 16212804 DOI: 10.1179/136485905x65099] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Affiliation(s)
- E Botelho-Nevers
- Service des Maladies Infectieuses et Tropicales, Hôpital Nord, Chemin des Bourrelys, 13915 Marseille Cedex 20, France
| | | | | | | |
Collapse
|